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ABSTRACT 
We synthesized 3-aroyl-1-arylpyrrole (ARAP) derivatives as potential anticancer agents having 
different substituents at the pendant 1-phenyl ring. Both the 1-phenyl ring and 3-(3,4,5-
trimethoxyphenyl)carbonyl moieties were mandatory to achieve potent inhibition of tubulin 
polymerization, binding of colchicine to tubulin and cancer cell growth. ARAP 22 showed strong 
inhibition of the P-glycoprotein-overexpressing NCI-ADR-RES and Messa/Dx5 MDR cell lines. 
Compounds 22 and 27 suppressed in vitro the Hedgehog signaling pathway, strongly reducing 
luciferase activity in SAG treated NIH3T3 Shh-Light II cells, and inhibited the growth of 
medulloblastoma D283 cells at nanomolar concentrations. ARAPs 22 and 27 represent a new potent 
class of tubulin polymerization and cancer cell growth inhibitors with the potential to inhibit the 
Hedgehog signaling pathway. 
INTRODUCTION 
Cancer is presently a major cause of death worldwide. The proportion of people suffering from 
cancer is estimated to continue rising, largely because of the aging of the population in most countries.1 
Antitumor agents in clinical use generally show cytostatic or cytotoxic activity through interference 
with mechanisms responsible for cell division. Despite enormous efforts, cancer remains one of the 
most difficult diseases to treat, as most patients obtain only a longer survival or no benefit at all from 
current cancer treatments. 
0LFURWXEXOHV07VDUH IRUPHGIURPĮȕ-tubulin heterodimers and play a fundamental role in 
numerous cell functions. MTs undergo a dynamic equilibrium, and preventing proper MT function by 
either inhibiting tubulin polymerization or blocking MT disassembly invariably causes cell death. 
Colchicine (1),2 combretastatin A-4 (CSA4, 2)3 (Chart 1), vincristine (VCR) and vinblastine (VBL) 
prevent MT assembly by inhibiting tubulin polymerization. Taxoids and epothilones instead target a 
lumenal site on the E-subunit.4 These drugs enter the lumen through a binding site5 located at a pore on 
the MT surface formed by different tubulin heterodimers. At high concentrations paclitaxel (PTX) 
stimulates MT polymerization and stabilization, whereas at lower concentrations it inhibits MT 
dynamics with little effect on the proportion of tubulin in polymer.6 
Interfering with MT formation or function has been a productive strategy for the development 
of highly successful antitumor drug classes.7 The classical antimitotic drugs are still one of the best 
approaches for cancer treatment. However, some problems related to drug resistance and to secondary 
toxicity still remain unsolved.9 Newer tubulin targeting agents have shown limited efficacy in clinical 
trials.8 Thus, the quest for better anticancer therapies based on alternative or synergistic anticancer 
drugs remains mandatory. 
 
 
Chart 1. 
 ? ?4. 
 
 
 
We have developed arylthioindole and aroylindole antimitotic agents as potent inhibitors of 
tubulin polymerization and of cancer cell growth.10 These compounds bind to the colchicine site on E-
tubulin and inhibit the binding of [3H]colchicine to tubulin.10 Several compounds of this class were 
more potent than 1, 2, VBL, and PTX, and have potential as novel therapeutic agents to treat cancer.10 
Splitting of fused rings by following a disjunctive approach often yields new biologically active 
chemical entities that show the same mechanism of action, weaker cytotoxicity and improved 
pharmacokinetic properties.11 This strategy allowed us to explore the potential of 3-aroyl-1-arylpyrrole 
(ARAP) derivatives as inhibitors of tubulin polymerization. In recent years, other groups have reported 
the discovery of tubulin binding agents sharing structural similarities to ARAPs.12 In light of these 
encouraging results we designed a prototypic molecule, 4, by disjunction of the indole ring of 3 into 1-
phenylpyrrole (Chart 1). 
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Since computer aided drug design was useful in the development of ATIs,10 4 was first 
evaluated by docking studies (Figure 1). In the proposed binding mode, the phenylpyrrole moiety of 4 
lay far from the indole of 3. ,WV ELQGLQJSRFNHW H[WHQGHGGHHS LQWR WKH ȕ-tubulin, so that its binding 
mode was similar to those of other colchicine site agents, for example ABT-751 (5),13 TN16 (6),13 
G2N (7),14 and K2N (8)14 (Chart 2). Nevertheless, the position of the trimethoxyphenyl (TMP) group 
of 3 and 4 was virtually identical. These results encouraged us to investigate further this new structure 
scaffold. 
 
 Figure 1. Binding mode of 4 (white) and parent compound 3 (cyan). The 
tubulin heterodimer is shown in strand format with pink for the D and blue 
for the Esubunit. Residues within 3.5 Å of the inhibitors are also shown. 
Residues (C241 and T179) involved in polar contacts are represented as the 
thicker sticks. 
 
 
The biological evaluation confirmed our initial idea since 4 proved to be a potent tubulin 
polymerization inhibitor with an IC50 of 1.5 PM. These results prompted hit optimization studies of 4 
by the synthesis of new ARAPs 9-55 (Table 1) and some correlated isomeric compounds 56-62 (Table 
1S, Supporting Information). Our data show that ARAPs are a new class of potent tubulin 
polymerization and cancer cell growth inhibitors that have potential as novel anti-cancer agents. 
 
CHEMISTRY 
Compounds 4, 10-20, 32-41, 45, 47-55 and 56-60 were prepared by microwave (MW)-assisted 
reaction of the appropriate 1-substituted pyrrole with 3,4,5-trimethoxybenzoyl chloride in the presence 
of anhydrous aluminum chloride in 1,2-dichloroethane at 110 °C (150 W) for 2 min (Scheme 1a). 
Treatment of benzaldehyde or its 3,4,5-trimethoxy derivative with an acetophenone and sodium 
hydroxide in ethanol at 25 °C for 12 h gave the trans-chalcones 82 or 83, which cyclized to pyrroles 61 
and 62 with p-toluenesulfonylmethyl isocyanide (TosMIC) in the presence of sodium hydride at 25 °C 
for 15 min in dimethyl sulfoxide (DMSO)/diethylether. Sodium hydroxide hydrolysis of 1-
phenylsulfonylpyrrole 55 by heating in methanol at reflux for 3 h furnished (1H-pyrrol-3-yl)-(3,4,5-
trimethoxyphenyl)methanone 9 (Scheme 1b). Tin(II) chloride dihydrate reduction of compounds 18-20 
or 45 for 3 h in boiling ethyl acetate afforded amino derivatives, 21-23 or 46, respectively (Scheme 1c). 
Isopropoxyphenyl pyrroles 38-40 were converted into the corresponding hydroxyphenyl derivatives  2-
44 by heating at reflux in chloroform with methanesulfonic acid for 2.5 h (Scheme 1c). 
Alkylation of 22 with dimethyl sulfate in acetone at 25 °C for 16 h in the presence of sodium 
carbonate gave 3-methyl (24) and 3-dimethylamino (26) derivatives that were separated by column 
chromatography (Scheme 2). Sodium cyanoborohydride reductive amination of 22 with acetone in 
methanol, tetrahydrofuran and aqueous hydrochloric acid at 25 °C for 12 h furnished 25. Treatment of 
22 with 1,4-dibromobutane or 1,5-dibromopentane in water in the presence of sodium carbonate at 
110 °C (100 W) for 20 min yielded the corresponding 3-(pyrrolidin-1-yl) (30) or 3-(piperidin-1-yl) (31) 
derivatives. The guanidino (27) and methanesulfonamido (28) derivatives were prepared by treating 22 
with cyanamide and 3.3 N hydrochloric acid in ethanol at 50 °C for 48 h or with methansulfonyl 
chloride in the presence of triethylamine (TEA) in tetrahydrofuran at 25 °C for 2 h, respectively.
 
Pyrrole derivative 29 was obtained according to the Clauson-Kaas reaction15 by treating the appropriate 
aniline with 2,5-dimethoxytetrahydrofuran in glacial acetic acid at 80 °C for 2 h. 
Scheme 1. Synthesis of Pyrroles 4, 9-23 and 32-62.a 
 
aReagents and reaction conditions (R1 and R2 see Table 1): (a) appropriate benzoyl 
chloride, AlCl3, 1,2-dichloroethane, closed vessel, 110 °C, 150 W, 2 min, yield 25-80%; (b) 
appropriate acetophenone, NaOH, EtOH, 25 °C, 12 h, 41-67%; (c) NaH, TosMIC, 
DMSO/Et2O, 25 °C, 15 min, 38-75%; (d) 2 N NaOH, MeOH, reflux, 3 h, 85%; (e)  SnCl2 ?2H2O, 
AcOEt, reflux, 3 h, 42-65%; (f) MeSO3H, CHCl3, reflux, 2.5 h, Ar, 28-51%;. 
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Scheme 2. Synthesis of Pyrroles 24-31.a 
 
aReagents and reaction conditions: (a) Me2SO4, Na2CO3, anhydrous acetone, 25 °C, 16 h, Ar, 
31%; (b) acetone, NaCNBH3, MeOH/THF, 6 N HCl, 25 °C, 12 h, 57%; (c) 1,4-dibromobutane, 
K2CO3, H2O, closed vessel, 110 °C, 100 W, 20 min, 35%; (d) 1,5-dibromopentane, K2CO3, 
H2O, closed vessel, 110 °C, 100 W, 20 min, 57%; (e) cyanamide, EtOH, 3.3 N HCl, 50 °C, 48 
h, 45%; (f) MeSO2Cl, TEA, anhydrous THF, 25 °C, 2 h, 49%; (g) 2,5-(MeO)2-THF, AcOH, 
80 °C, 2 h, 82%. 
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Scheme 3. Synthesis of Intermediates 63-81.a 
 
aReagents and reaction conditions: (a) (63 R3 = 2-Cl; 64 R3 = 3-Cl; 65 R3 = 3-NO2; 66 R3 = 
2-Me; 67 R3 = 3-Me; 68 R3 = 4-Me; 69 R3 = 2-OMe; 70 R3 = 3-OMe; 71 R3 = 2-OCHMe2; 72 
R3 = 3-OCHMe2;  73 R3 = 4-OCHMe2; 74 R3 = 3-OCH2Ph; 75 R3 = 4-OMe,3-NO2; 76 R3 = 3-
OCHMe2,4-OMe; 77 R3 = 3,4-OMe2; 78 R3 = 3,4,5-OMe3) 2,5-OMe2THF, AcOH, 80 °C, 2 h, 
34-72%; (b) 2-iodopropane, K2CO3, anhydrous DMF, 50 °C, 3 h, Ar stream, 76%; (c)  ?2O, THF/H2O, 25 °C, 12 h, 77%; (d) SOCl2, reflux, 1.5 h, Ar stream, used as a crude 
product. 
 
 
 
Pyrrole derivatives 63-78 were obtained from an appropriate aniline and 2,5-
dimethoxytetrahydrofuran under the aforementioned conditions of the Clauson-Kaas reaction (Scheme 
3a). Reaction of methyl 3-hydroxy-4-methoxybenzoate with 2-iodopropane in DMF in the presence of 
potassium carbonate at 50 °C for 3 h furnished derivative 79. Lithium hydroxide hydrolysis of 79 in 
aqueous tetrahydrofuran at 25 °C for 12 h afforded the acid 80, which was converted to the 
corresponding acid chloride 81 by treatment with thionyl chloride at reflux temperature for 1.5 h 
(Scheme 3b). 
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RESULTS AND DISCUSSION 
Inhibition of Tubulin Polymerization, the Binding of Colchicine to Tubulin and MCF-7 
Breast Cancer Cell Growth. We synthesized ARAP compounds 4 and 9-55 to obtain structure-
activity relationship (SAR) information regarding position and substituents on both the aroyl and aryl 
aromatic moieties. The effects of these compounds on tubulin polymerization in vitro, the binding of 
[3H]colchicine to tubulin and the growth of MCF-7 human breast cancer cells are shown in Table 1. 
Sixteen new ARAPs (4, 15, 17, 22-24, 26, 27, 36, 37, 42-44, 46, 47 and 49) inhibited tubulin 
polymerization with IC50 YDOXHVLQWKHíȝ0FRQFHQWUDWLRQUDQJH&RPSRXQGV15, 24, 28, 33 and 
34 yielded IC50 YDOXHVȝ0DVFRPSDUHGZLWKFROFKLFLQH1) (IC50  ȝ0DQG&6$2) (IC50 = 
ȝ0&RPSRXQGVODFNLQJWKHSHQGDQW-phenyl ring (9, 10) or the 3,4,5-trimethoxy group (11) did 
not inhibit tubulin assembly, emphasizing the essential role of these moieties for the anti-tubulin 
activity of ARAPs. Introduction of either a chlorine or fluorine atom on the 1-phenyl ring yielded 
potent tubulin polymerization inhibitors (compounds 12-17). However, regardless of the position of the 
halogen atom, these compounds were moderate to weak inhibitors of the growth of human MCF-7 non-
metastatic breast cancer epithelial cells. Among the nitrophenyl derivatives, only 1-(3-
nitrophenyl)pyrrole 19 showed significant inhibition of tubulin polymerization with an IC50 RIȝ0 
Reduction of the nitro group of 19 provided the corresponding amino derivative 22, and this 
compound potently inhibited tubulin assembly (IC50    ȝ0 0RUH LPSRUWDQWO\ FRPSRXQG 22 
inhibited MCF-7 cell growth with an IC50 of 15 nM, 10-fold lower than the value obtained for reference 
compound 3, comparable with the value for 2 and only 3-fold higher than that of 1. For SAR studies 
regarding the 1-(3-aminophenyl)pyrrole 22, we synthesized ARAP derivatives 24-31. With the 
exception of 27, these derivatives potently inhibited tubulin polymerization with IC50 YDOXHVPM, 
with compound 28 (IC50  ȝ0EHLQJ WKHPRVWSRWHQW WXEXOLQDVVHPEO\ LQKLELWRUDPRQJDOO WKH
ARAPs. As inhibitors of MCF-7 cell growth, 24, 25 and 27-30 yielded IC50 values from 16 (30) to 60 
nM (28), and three compounds (25, 27 and 30) were comparable to 22. 
Introduction of a methyl on the 1-phenyl group led to potent tubulin polymerization (33, IC50 = 
0.95 PM; 34, IC50 = 0.90 PM) and cancer cell growth inhibitors (33, IC50 = 50 nM; 34, IC50 = 29 nM). 
Replacement of the methyl group with a methoxy also provided potent inhibitors (35-37), at least of 
tubulin polymerization (IC50's = 2.7, 1.8 and 1.2 PM, respectively, for 35, 36 and 37). Compounds 35-
37 were, however, only moderate to weak inhibitors of MCF-7 cell growth. The hydroxyphenyl 
derivatives 42-44 strongly inhibited the polymerization of tubulin, with IC50 values in the low 
micromolar concentration range. Considering the typical substitution pattern of 2 and its amino 
derivatives, we synthesized two potent tubulin assembly inhibitors (both with IC50¶VRI0-(3-
amino-4-methoxyphenyl)- (46) and 1-(3-hydroxy-4-methoxyphenyl)pyrroles (47). Compounds 42-49 
were weak inhibitors of MCF-7 cell growth. Compounds 50-55 and, similarly, the isomeric 2-aroyl-1-
arylpyrroles (56-60) and 3-aroyl-4-arylpyrroles (61, 62) all had little or no effect on tubulin 
polymerization (Table 1S, Supporting Information) and were not studied further. 
In general, inhibition of colchicine binding was in accord with inhibition of tubulin binding 
(Figure 2). The compounds that inhibited assembly with IC50 YDOXHV  ȝ0 LQKLELWHG FROFKLFLQH
binding (with tubulin at 1 µM and both colchicine and inhibitor at 5 µM) by 77-95%. Assembly 
inhibitors in the 1.0-1.5 µM range, inhibited colchicine binding by 48-89%; those that inhibited 
assembly with IC50¶VLQWKH-2.0 µM range, inhibited colchicine binding by 48-67%; and assembly 
inhibitors with IC50¶VLQWKH-2.7 µM range, inhibited colchicine binding by 17-58% (CSA4: IC50 = 
1.0 µM, colchicine binding inhibition = 98%).3 While the correlations between the three assays in 
Table 3 are reasonable, they are not perfect. For example, the best inhibitor of assembly was compound 
28 (IC50, 0.86 µM), the best inhibitor of colchicine binding was compound 34 (95% inhibition) and the 
best inhibitors of MCF-7 cell growth were compounds 22 and 23 (IC50¶VQ0Nevertheless, these 
compounds, among others, had excellent activity in all three assays. 
 Figure 2. Correlation between tubulin assembly (IC50 values , PM) and inhibition of colchicine binding (% values). 
data of ARAP compounds 4 and 9-55 (open circles). CSA4 as reference compound is represented by a filled circle. 
 
 
  
Table 1. Inhibition of Tubulin Polymerization and the Binding of Colchicine to Tubulin and Inhibition 
of Growth of MCF-7 Human Breast Carcinoma Cells by 3-Aroylpyrroles 4, 9-55 and Reference 
Compounds 1-3.a 
 
 
compd R1 R2 
Tubulin 
Assemblya 
IC50 ± SD 
(PM) 
MCF-7b,c 
IC50 ± SD 
(nM) 
Colchicine 
Bindingd 
(% ± SD) 
4 
 
 
1.5 ± 0.2 
 
700 ± 200 
 
80 ± 2 
9  H 
 
>40 nd f nd 
10 Me 
 
>40 nd  nd 
11 
  
>20e nd f nd 
12 
 
 
8.8 ± 0.1 4500 ± 700 nd 
13 
 
 
2.2 ± 0.2 600 ± 0 58 ± 4 
14 
 
 
2.3 ± 0.02 200 ± 100 73 ± 2 
15 
 
 
1.0 ± 0.08 1000 ± 300 77 ± 2 
16 
 
 
2.1 ± 0.2 1300 ± 400 55 ± 5 
N
O
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R1
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MeO
MeO
MeO
MeO
MeO
MeO
MeO
MeO
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MeO
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17 
 
 
1.4 ± 0. 2 190 ± 40 78 ± 2 
18 
 
 
>20 e nd nd 
19 
 
 
8.9 ± 1 230 ± 60 nd 
20 
 
 
>20 e nd nd 
21 
 
 
6.8 ± 0.8 nd nd 
22 
 
 
1.4 ± 0.2 15 ± 5 86 ± 2 
23 
 
 
1.3 ± 0.8 15 ± 1 81 ± 1 
24 
 
 
1.0 ± 0.04 30 ± 10 92 ± 0.7 
25 
  
2.5 ± 0.04 20 ± 0 53 ± 1 
 26 
  
1.5 ± 0.2 1000 ± 0 60 ± 4 
27h   
  
1.2 ± 0.1 20 ± 0 87 ± 0.8 
28 
  
0.86 ± 0.06 60 ± 30 84 ± 0.5 
29 
  
2.5 ± 0.07 43 ± 20 27 ± 4 
30 
  
2.5 ± 0.05 16 ± 6 23 ± 4 
F MeO
MeO
MeO
NO2
MeO
MeO
MeO
O2N
MeO
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31 
  
>20 e nd nd 
32 
 
 
13 ± 1 nd nd 
33 
 
 
0.95 ± 0.02 50 ± 0 79 ± 1 
34 
 
 
0.90 ± 0.04 29 ± 10 95 ± 0 
35 
 
 
2.7 ± 0.5 3500 ± 700 50 ± 3 
36 
 
 
1.8 ± 0.2 600 ± 0 66 ± 3 
37 
 
 
1.2 ± 0.2 250 ± 70 76 ± 5 
38 
  
6.1 ± 1 nd nd 
39 
  
2.5 ± 0.2 250 ± 50 17 ± 0.01 
40 
 
 
>20 g nd nd 
41 
 
 
>20 g nd nd 
42 
 
 
1.7 ± 0.03 530 ± 100 67 ± 0.6 
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1.2 ± 0.1 400 ± 100 86 ± 0.4 
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1.7 ± 0.1 450 ± 200 59 ± 1 
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15 ± 0.07 830 ± 200 nd 
46 
 
 
1.3 ± 0.01 470 ± 200 89 ± 0.2 
47 
 
 
1.3 ± 0.04 4500 ± 700 79 ± 3 
48 
 
 
2.1 ± 0.2 100 ± 0 56 ± 0.1 
49 
  
1.7 ± 0.2 1700 ± 1000 48 ± 6 
50 
 
 
>20 g nd nd 
51 
  
>40 nd nd 
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>20 e nd nd 
53 
  
>20 e nd nd 
54 
 
 
>40 nd nd 
55 
 
 
16 ± 0.6 nd nd 
1 Ȅ Ȅ 3.2 ± 0.4 5 ± 1 nd 
2 Ȅ Ȅ 1.0 ± 0.1 13 ± 3 98 ± 0.6 
3i Ȅ Ȅ 3.5 ± 0.07 150 ± 50 26 ± 0.3 
a Ǥ   ? ?Ɋ ǤbInhibition of growth of 
MCF-7 human breast carcinoma cells. cCompounds that inhibited tubulin assembly with IC50  ? ? Ɋ 
tested in the cellular and colchicine binding assays. dInhibition of [3ȐǤ ?ɊǤ
Both [3Ȑ ?ɊǤePartial inibition at 20 µM. fno data. gLittle or no activity at 20 
PM. hHydrochloride. iLit.10a. 
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Table 2. Growth Inhibition of HeLa, HT-29, A549 and HCT116 Cell Lines by 
Compounds 4, 22, 35-37, 47 and 49 and Reference Compounds 1, 2, VBL and PTX.a 
 
  IC50 ± SD    
compd HeLA HT-29 A549 HCT116 
4 100 ± 18 90 ± 10 200 ± 50 77 ± 4 
22 30 ± 1 60 ± 1 10 ± 4 ndb 
35 900 ± 70 1000 ± 1400 1000 ± 300 nd 
36 1000 ± 110 800 ± 20 3000 ± 500 nd 
37 150 ± 1 200 ± 20 80 ± 7 nd 
47 200 ± 10 >10000 >10000 nd 
49 800 ± 033 800 ± 1 1000 ± 20 nd 
1c 28 ± 9 18 ± 4 20 ± 8  20 ± 2 
2 c 20 ± 5 130 ± 12 >10000 5 ± 0.4 
VBL c 10 ± 0.6 30 ± 0.8 20 ± 2 3 ± 2 
PTX c 5 ± 1 8 ± 1.5 7 ± 2 4 ± 0.4 
aGrowth inhibition of the indicated cell lines (MTT method); incubation time was 48 h. 
bno data. cLit.10b 
 
 
ARAPs 4, 22, 35-37, 47 and 49 were evaluated for growth inhibition of HeLa (human cervical 
carcinoma), HT29 (human colon adenocarcinoma), and A549 (human lung carcinoma) cells in 
comparison with 1, 2, VBL and PTX (Table 2). With the exception of 47, and ignoring the high value 
obtained with 2 in the A549 cells, the compounds were uniformly inhibitory against the panel. When 
evaluated as inhibitor of HCT15 cells, the drug resistant cell line of HCT116 (human colon carcinoma 
cells), compound 4 yielded an IC50 of 39 ± 4 nM (data not shown in Table 2). The most potent ARAP 
22 was of similar potency to 1 and VBL as inhibitor of the growth of HeLa, HT-29 and A549 cells. 
 
Table 3. Inhibition of Growth of the OVCAR-8 and NCI/ADR-RES, and Messa and 
Messa/Dx Cell Line Pairs by Compounds 4, 22, 27 and 35-37, and Reference 
Compounds 1, 2, VRB, VBL and PTX.a 
 
  IC50 ± SD  (nM)  
compd OVCAR-8 NCI/ADR-RES   Messab Messa/Dx5b 
4 45 ± 20 20 ± 0 56 ± 3 76 ± 7 
22 7.0 ± 1 1.0 ± 0 1.8 ± 0.2 4.6 ± 0.3 
27c ndd nd 14 ± 4 16 ± 0.02 
35 450 ± 70 200 ± 0 515 ± 29 653 ± 143 
36 250 ± 70 90 ± 10 262 ± 74 471 ± 58 
37 60 ± 20 17 ± 6 63 ± 7 87 ± 21 
1 30 ± 1 420 ± 100 11 ± 6 329 ± 166 
2 1.3 ± 0.6 1.3 ± 0.6 2.7 ± 2 2.6 ± 1 
VRB 300 ± 0 5000 ± 1000 ndc nd 
VBL 15 ± 7 200 ± 0 3 ± 2 144 ± 61 
PTX 5.0 ± 2 3300 ± 1000 4 ± 1 1764 ± 477 
aInhibition of growth of the indicated cell lines. bGrowth inhibition data of compounds 
11, 12, 14, 18, 19, 27, 29, 38 and 51 are shown in Table 2S, Supporting Information. 
bHydrochloride. cno data. 
 
 
 
Compounds 4, 22, 27 and 35-37 were evaluated as inhibitors of the ovarian carcinoma cell lines 
OVCAR-8 and its cognate P-glycoprotein (Pgp) overexpressing line NCI/ADR-RES and of the human 
uterine sarcoma cell line Messa and its cognate MDR line Messa/Dx5, using 1, 2, vinorelbine (VRB), 
VBL and PTX as reference compounds (Table 3). With the exception of 2, the reference agents were 
quite weak inhibitors of the MDR cell lines. ARAP 22 showed strong inhibition of MDR cells and was 
at the same level as 2. 
 
Molecular Modeling Studies. To better understand the ARAPs binding mode, a series of 
molecular docking simulations were carried out. Among the available tubulin crystal structures with 
colchicine site inhibitors,13 3HKD16 was selected because of the structural similarity between the co-
crystallized ligand and 4. The results obtained for compound 4 showed that the phenyl group was 
stabilized by a series of hydrophobic/aromatic contacts in a pocket formed mainly by the Y52, F169, 
Y202, V238 and L251 side chains; the pyrrole core was stabilized by L255, V238 and I378. 
Furthermore, we observed a weak H-bond interaction between the Y202 OH group and the S-aromatic 
cloud of the pyrrole. Interestingly, from the docking results, it appears that the ketone bridge is not 
involved in any interactions. Finally, the TMP moiety was in contact with residues C241, L245, L255, 
M258, A316 and A317 (Figure 1S, Supporting Information). 
  
Figure 3. Cell cycle arrest in HeLa cells after treatment with either 4 or 22. A. Flow cytometric analysis of the cell 
cycle phase distribution in HeLa cell cultures after the indicated treatments. The histograms show mean values, and 
bars standard deviations, of cells with 2C (G1 phase), 4C (G2/M phases) or intermediate (S phase) DNA content 
detected by PI incorporation in 3 independent experiments. B. Typical views from live, unfixed HeLa cell cultures 
under light microscopy (10 x objective): 4 and 22, as well as VLB, induced an accumulation of rounded, detached cells, 
as occurs in mitotic arrest (compare to the adherent cells in the control (DMSO-treated) culture).  
 
 
 
Induction of Mitotic Arrest and Cell Death in HeLa Cell Cultures. The ability of the ARAP 
molecules 4 and 22 to arrest mitotic progression was assessed in HeLa cells. HeLa cell cultures were 
treated for 24 h with 4 or 22, both used at 20 and 100 nM; VBL (20 nM) or 2 (20 nM) were used as 
reference compounds. Treated and untreated samples were first incubated with propidium iodide (PI) to 
analyze their genomic content in flow cytometry assays. We found that both 4 and 22 effectively 
arrested cell cycle progression when used at 100 nM, with the majority of cells accumulating with 4C 
DNA content, hence in the G2 or M phases (Figure 3A). At the 20 nM concentration, 22 proved to be 
as effective as VBL and 2, whereas 4 had only a minimal effect (data not shown). Light microscopy 
revealed that the majority of cells in treated cultures displayed a typical mitotic, rounded-up phenotype 
(Figure 3B), consistent with the cells being blocked in mitosis. 
The effects of ARAPs on mitotic cells were observed by immunofluorescence (IF) methods 
(Figure 4). Both ARAPs 4 and 22 inhibited normal spindle formation, such that cells progressed 
normally into mitosis through nuclear envelope breakdown (depicted by the absence of lamin B1 
staining), but treated cells failed to organize a proper mitotic apparatus and arrested with condensed 
chromosomes in a prometaphase-like state (Figure 4A). Noteworthy, 100 nM 4 and 20 nM 22 had 
similar effects, yielding evidently defective MTs that failed to form a normal mitotic spindle (Figure 
4A, panel A): short MTs were formed, often arranged in aberrantly shaped, tripolar (Figure 4A, panel 
B) or multipolar (Figure 4A, panel C) structures. The abnormal MT structures failed to cause sustained 
PLWRWLFDUUHVW LQVRPHFHOOVPLWRWLF³VOLSSDJH´VXFKFHOOVSURJressed towards aberrant cell division, 
eventually producing multi- and micronucleated daughter cells (Figure 4B). Only unstructured tubulin 
foci were seen with 100 nM 22, while MT elongation failed completely; under these conditions, the 
occurrence of mitotic slippage dropped significantly, in the same range as observed with 2 (data not 
shown).  
 
 Figure 4.  Inhibition of normal spindle formation by 4 and 22. A. Mitotic cells were identified by the lack of lamin B1 
staining (red channel) and the organization of condensed chromosomes (blue channel) similar to those seen in a 
normal prophase (depicted in panel a). Representative examples from treated cultures are shown (panels b-d). B. 
Frequency of mitotic figures (M) and micronucleated cells (MN), representing the products of mitotic slippage, in 
HeLa cultures treated as indicated. At least 500 cells per condition were scored in two independent experiments; 
mean and SD values are shown. C. Frequency of annexin V-reactive HeLa cells under the indicated conditions. 
Histograms represent mean values and bars standard deviations from 3 independent flow cytometry assays.   
In order to determine whether ARAP-dependent MT damage induced cell death in treated 
cultures, we used fluorescently conjugated annexin V, which reveals the loss of organization of the cell 
membrane occurring in early cell death stages. Cell death was activated in cell populations treated by 
both ARAPs in proportions similar to those observed with VBL (Figure 4C). In summary, both ARAPs 
prevented mitotic MT organization into normal spindles and blocked mitotic progression in HeLa cells 
with concomitant activation of cell death. Compound 22 proved to be more effective than 4 and was 
comparable to VBL. With 100 nM 22, a reduction of mitotic slippage was observed with no effect on 
mitotic arrest or cell death induction. 
The cell cycle inhibitory effects of 4 in HeLa cells, albeit less pronounced than those of 22, were 
significant and dose-dependent (Figure 3A). This differential response might have reflected a 
requirement for caspase-3 activity, which influences the cell response to MT-targeting drugs,17 yet is 
defective in the MCF-7 cell line. Therefore, we compared the effects of 4 in MCF-7 and in a MCF-7-
derived cell line stably expressing an exogenous caspase-3 gene (MCF-7/cas 3).18 However, by flow 
cytometry no differences between the caspase-3-reconstituted and the native MCF7 cell lines were 
detected in either cell cycle profile or in annexin V reactivity after treatment with 100 nM 4 (data not 
shown). We carried out a single cell analysis after IF staining of D-tubulin, to stain mitotic MTs, and of 
active caspase-3 using a specific antibody to the processed form of the enzyme, to evaluate cell death. 
The IF analysis confirmed that 100 nM 4 induced mitotic arrest and cell death in HeLa cells, but neither 
in MCF-7 nor in MCF-7/cas-3 parallel cultures treated under the same conditions. These data account 
for the very high IC50 value detected in the cell viability assays and rule out the possibility that caspase-
3 would be the limiting factor in this response, suggesting that MCF-7 cells are intrinsically resistant to 
MT inhibition by 4. 
Table 4. Growth Inhibition of PC-3, RD and HepG2 Cell Lines 
by Compounds 22 and 27, and Reference Compounds VBL, 
VCR and PTX.a 
 
  IC50 ± SD (nM)  
compd PC-3 RD HepG2 
22 9.8 ± 5.5 95.3 ± 1.7 274.5 ± 4.8 
27 3.9 ± 1.9 803.2 ± 1.9 49.5 ± 1.8 
VBL ndb 52.5 ± 2.5 80.7 ± 2.4 
VCR ndb nd 177 ± 1.6 
PTX 3990 ± 1.9 14200 ± 1.6 2037 ± 2 
  aGrowth inhibition of the indicated cell lines (MTT method); 
incubation time was 48 h bno data.  
 
 
 
Inhibition of PC-3, RD and HepG2 Cancer Cell Growth. We wished to determine whether 
the effect of ARAPs on cell cycle distribution was observed more generally. Therefore, compounds 22 
and 27 were evaluated as inhibitors of the growth of the rhabdomyosarcoma cell line RD, the human 
prostate cancer cell line PC-3 and the human liver hepatocellular carcinoma cell line HepG2 with VCR, 
VBL and PTX as reference compounds (Table 4). ARAP 22 and 27 showed strong inhibition of these 
three cell lines as compared with PTX. Moreover, as an inhibitor of HepG2 cell growth, 27 was more 
effective than VCR and VBL.  
 
 
 Figure 5. Cell cycle analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% DMSO or 500, 1000 or 2000 
nM PTX, VBL, VCR, 22 and 27 for 24 h. Representative cell cycle profiles derived from flow cytometric analysis of cell 
populations following treatment with DMSO or 2000 nM 22 and 27 are shown in the upper part of each panel. 
Histograms show the percent of cells with G0/G1, S and G2/M DNA content expressed as mean values ± SD 
calculated from three independent experiments. 
  
 
 
 
 
Figure 6.  Cell cycle analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% DMSO or 500, 1000 or 2000 
nM PTX, VBL, VCR, 22 and 27 for 24 h and harvested after a further 24 h recovery in drug-free medium. Histograms 
show the percent of cells with G0/G1, S and G2/M DNA content expressed as mean values ± SD calculated from three 
independent experiments. 
 
 
Effects on Cell Cycle Progression in the PC-3, RD and HepG2 Cell Lines. ARAP molecules 
22 and 27 were evaluated in PC-3, RD and HepG2 cells, and accumulation of G2/M cells was observed 
in all of these cell lines (Figure 5). PC-3, RD and HEPG2 cell cultures were treated for 24 h with 
increasing concentrations (500, 1000 and 2000 nM) of 22, 27 and the reference compounds PTX, VBL 
and VCR. Treated cells and vehicle controls (0.1% DMSO) were incubated with PI to analyze their 
DNA content in flow cytometry assays.  
We found that both 22 and 27 effectively arrested cell cycle progression at the lowest 
concentration in the three cell lines. Nevertheless, there were differences in cell cycle distribution. As 
shown in Figures 5A and 5B, 22 and 27 induced an accumulation in G2 or M phase in PC-3 and RD 
cells that differed little from the patterns observed with the reference compounds. In contrast, in HepG2 
cells, 22 and 27 caused a stronger effect on cell cycle progression as compared with PTX (Figure 5C). 
The significant increase in the proportion of cells in the G2/M phase was also reflected in abundant 
rounded cells observed under the light microscope in all cases. This indicates that ARAPs 22 and 27 
exerted a selective action specifically at mitosis 
Sequential treatment of PC-3, RD and HepG2, consisting of 24 h exposure to 22, 27, or the 
reference compounds, followed by incubation in drug-free medium for 24 h, revealed a differential 
behavior in the cell lines analyzed. As shown in Figure 6A and 6B, except for RD cells following the 
500 nM treatment, ARAPs induced an irreversible cell cycle arrest. In contrast, a substantial recovery 
of cell cycle progression, following drug washout, at all doses and with all compounds evaluated, was 
observed with the HepG2 cell line (Figure 6C). This indicates that a 24 h treatment with 22 or 27, or 
even the reference compounds, might be relatively ineffective in the HepG2 cell line. 
 
  
  
 Figure 7. Cell death flow cytometric analysis of PC-3 (A), RD (B) and HepG2 (C) cells treated with 0.1% DMSO or 
500, 1000 or 2000 nM PTX, VBL, VCR, 22 or 27 for 48 h.  Flow cytometric profiles of cell populations following 
treatment with DMSO or 2000 nM 22 or 27 are shown  in the upper part of each panel (annexin- apoptosis (annexin 
V-FITC staining) and in late apoptosis (annexin V-FITC and PI staining) expressed as mean values ± SD calculated 
from three independent experiments.  
Compound Effects on Cell Viability in the PC-3, RD and HepG2 Cell Lines. In order to 
reveal whether ARAPs-dependent cell cycle arrest was associated with cell death, treated cells were 
incubated with fluorescently conjugated annexin V and PI. Comparable levels of cell death were 
triggered in cell populations treated with 22, 27 or with PTX, VBL or VCR at all doses examined 
(Figure 7). A dose-response trend in cell death was observed only in the PC-3 cell line following 48 h of 
exposure to 27 and in the HepG2 cell line following treatment with PTX. Although a similar dose-
dependent effect in RD and HepG2 cells was not observed with either ARAP, a stronger impact of both 
ARAPs on cell viability, in comparison with PTX, did occur. 
Survey of a Larger Number of ARAPs for Specific Antitubulin Activity, as Measured by 
Mitotic Index (MI) Studies in K562 Human Leukemia Cells. The studies above showed that 
compounds 4, 22 and 27 were clearly antitubulin agents, causing mitotic arrest, cellular microtubule 
disruption and/or apoptosis. These are well-defined characteristics of a wide variety of antitubulin 
compounds.  Nevertheless, we cannot readily exclude other targets for the other ARAPs.  We therefore 
decided to do a MI study with additional compounds, comparing them with 22 and 27 as well as the 
extensively studied 2. We selected the human leukemia K562 line for this analysis, and the data are 
summarized in Table 5. We chose an additional six strong inhibitors of tubulin assembly (compounds 24, 
25, 28, 29, 30 and 34) with IC50¶VDJDLQVWWKH0&)-7 cells ranging from 16 to 60 nM. In the K562 cells, 
the IC50¶VRIWKHVHFRPSRunds ranged from 14 to 950 nM. We planned to obtain MIs at 10 times the IC50 
value, but we were technically limited to a maximum concentration of 4 µM (due to toxicity of DMSO 
for the cells). In all cases elevated MIs were obtained, ranging from 39-73%, with the lowest value 
obtained with compound 30, where the concentration was only 4.2 times the IC50 value. Untreated cells 
yielded a MI of 3%. A high MI in drug-treated cells is a hallmark of antitubulin agents, and this finding 
makes it unlikely that an additional intracellular target plays a significant role in the cytotoxicity 
observed with these ARAPs. 
Table 5. Mitotic Index Values of ARAPs 22, 24, 25, 27-30 and 34. 
 
 
IC50 ± SD  
 
Mitotic Index ± SD 
compd 
 
K562 
 
(concentrationa) 
22  20 ± 6  60 ± 9 (at 10x IC50) 
24  30 ± 0  61 ± 1 (at 10x IC50) 
25  500 ± 100  b) 
30  950 ± 100  c) 
27  25 ± 7  71 ± 8 (at 10x IC50) 
28  19 ± 8  61 ± 1 (at 10x IC50) 
29  90 ± 10  47 ± 1 (at 10x IC50) 
34  30 ± 0  61 ± 1 (at 10x IC50) 
2   nd   
controld  -  3 ± 1 
aHighest concentration possible in mitotic index study was 4.0 µM. 
bIC50, 500 ± 100 nM. cIC50 950 ± 100 nM. dUntreated cells. 
 
 
Hedgehog Inhibiting Activity. In recent years, inhibitors of the Hedgehog (Hh) molecular 
signaling pathway have emerged as a new compound class with chemotherapeutic potential. A variety 
of small molecules targeting different components of the Hh pathway, i.e., Smoothened (Smo), Sonic 
hedgehog protein (Shh), and Gli1, have been identified.19 A number of inhibitors of the Smo receptor, 
the positive signaling transducer in the Hh signaling pathway, are presently in clinical trials. 
We speculated that ARAPs may represent constraint analogues of MRT (i.e., 84 (MRT-10) and 
85 (MRT-14)) Smo antagonists.20,21 (Chart 3). To validate this hypothesis we carried out a series of in-
silico simulations (molecular docking and pharmacophore matching) on the Smo receptor to compare 
the structural features of ARAPs with 84 and 85. The docking results for both 4 and 85 showed that the 
TMP could be stabilized by hydrophobic contact with F484, M301, L221, W480 and P513. 
Chart 3. MRT-ARAP Structure Relationships. 
 
 
 
Figure 8. Binding mode of 85 (cyan) and ARAP 4 (purple). Smo is shown as ribbon 
(green), residues within 3.5 Å are shown as grey lines, while residues involved in H-bonds 
are shown as grey sticks.  
 
 
 
Furthermore, an H-bond contact between the 4-methoxy group of the two different compounds with 
N219 it was also present (Figure 8). The carbonyl bridge also establishes an H-bond with the R400 
residue. The pyrrole ring of compound 4 occupies the same space as the urea moiety of 85, although 
ring
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the pyrrole is mainly stabilized by Y394 and V386. Finally, the phenyl ring of both structures is in 
close contact with I389, M330, W281 and E517.  
Our modeling studies propose a potential binding mode of ARAP compounds on the Smo 
receptor. Yet, the proposed docking poses are in accordance with those of MRT derivatives20 as 
reference for the modeling studies. The pharmacophore matching showed clearly that 4 of the 6 
features were satisfied by 4, namely the TMP group fits into the F2:Acc and F3:Hyd features; the 
carbonyl matches the F4:Acc features; and the phenyl rings overlap with the F4:Hyd feature (Figure 2S, 
Supporting Information). The convergent results observed for the docking and pharmacophore studies 
suggested that the newly designed ARAPs could mimic the biological activity of the MRT compounds. 
Compounds 22 and 27 showed the highest score in the ARAP series, so they were selected to 
characterize the inhibitory properties of ARAP compounds on the Hh signaling pathway. 
We examined the effects of 22 and 27 in NIH3T3 Shh-Light II (Shh-LII) cells stably 
incorporating an Hh-responsive (Gli-RE) reporter, in which induction of the pathway occurs following 
treatment with the Smo agonist SAG. This in vitro test, widely used to for characterizing Hh inhibitors, 
revealed that compounds 22 and 27 strongly reduced luciferase activity in cells treated with SAG in a 
dose-dependent manner (Figure 9) and showed the ability of both compounds to suppress the signaling 
pathway. In these assays, compound 22 yielded an IC50 of 676 nM and 27, an IC50 of 682 nM. We 
excluded the possibility that inhibition of Hh signaling in this assay was mediated by cytotoxicity, 
because the investigated compounds did not decrease the control Renilla luciferase activity. 
Hh inhibitors have shown benefits in the treatment of Hh-dependent cancers, such as 
medulloblastomas.19 However, new Hh inhibitors are desired to overcome the problem of drug resistant 
Smo mutations arising during treatment. ARAPs 22 and 27 inhibited the growth of medulloblastoma 
D283 cells with IC50 values of 580 ± 150 nM and 675 ± 325 nM, respectively. These findings suggest 
that ARAPs can be developed as potential Hh-dependent anticancer agents. 
 Figure 9. Inhibition of endogenous Hh signaling in Shh-L II cells by 22 and 27. DoseȂresponse curve of the indicated 
compounds in SAG-treated cells in comparison with untreated NIH3T3 Shh-Light II cells. Treatment time was 48 h, 
and normalization was against Renilla luciferase. Data from three independent experiments. Error bars indicate SD. 
*P, 0.05 vs CTR. 
 
 
 
 
Pharmacokinetic Studies. Intravenous pharmacokinetics and oral bioavailability of 22 was 
performed in a mouse model. Compound 22 showed a high clearance and a very high volume of 
distribution in the mouse after intravenous (IV) treatment at 5 mg/kg (Table 6, top panel). The average 
time spent between infusion and elimination (mean residence time, MRT) was about 31 min, whereas 
the elimination half-time (T1/2) was 74 min. After per os (PO) administration, the profile of 22 showed 
a very rapid absorption (Tmax = 5 min, time to reach Cmax), long MRT = 145 min, and oral 
bioavailability of 49% (Table 6, bottom panel). In Supporting Information are reported the profiles of 
distribution in plasma of 22 after IV infusion and PO administration (Figure 3S, Supporting 
Information), and a comparison of the kinetic profiles (Figure 4S, Supporting Information).  
 
 
 Table 6.  Pharmacokinetic parameters for ARAP 22. 
IV Infusion Value 
Cmax IV (ng/mL) 3404 
Co (ng/mL) 4152 
T1/2 (min) 74 
Tlast (min) 480 
Clast (ng/mL) 2.3 
MRT (min) 31 
Cl (mL/min/kg) 80.8 
Vdss (L/kg) 2.7 
AUC 0-480 IV (min.ng/ml) 61660 
AUCinf IV (min.ng/ml) 61906 
PO Administration Value 
Cmax PO (ng/mL) 1767 
Tmax PO (min) 5 
Tlast (min) 480 
Clast (min) 34 
T1/2 (min) 179 
MRT (min) 145 
AUC 0-480 PO (min.ng/mL) 79441 
AUCinf PO (min.ng/mL) 88183 
Mean Fpo last (%) 49 
 
 
Caco-2 Cell Permeability. The intestinal permeability of compound 22 was evaluated in the 
human Caco-2 model in comparison with caffeine (high permeability) and cimetidine (low 
permeability, Pgp substrate). The apparent permeability (Papp) of 22 from the A (apical) to B 
(basolateral) side together with B to A was measured in order to predict the absorption from the lumen 
of the gut and potential efflux phenomena. Compound 22 showed high permeability in both the $ĺ%
3DSS QPVDQG%ĺ$3DSS QPVGLUHFWLRQV7DEOH7). Compound 22 did not show 
HIIOX[SKHQRPHQDLHUDWLRRI3DSS%ĺ$WR3DSS$ĺ%RI 
 
Table 7. Caco-2 Cell Permeability and CYP450 Isoform Inhibition of Compound 22. 
 Papp  (nm/s)a  CYP450 Isoform (% inhibition at 1 PM) 
compd PAĺB PBĺA  CYP1A2 CYP2C19 CYP2C9 CYP2D6 CYP3A4 
22 123.2 107.3  66.8 72.6 28.9 <5.0 12.2 
aPapp (nm/s): >50, high; 10-50, medium; <10, low; caffeine PA-B reference control, 206 ± 35 nm/s; cimetidine PA-B 
and PB-A reference control, 1.1 ± 0.1 and 21.3 ± 3.4 nm/s, respectively. 
 
 
CYP450 Inhibition. The inhibition of the enzymatic activity of human cloned P450 isoforms 
CYP1A2, CYP2C19, CYP2C9, CYP2D6, and CYP3A4 by 22 was measured using specific substrates 
for each isoform that produced a fluorescent metabolite upon CYP metabolism. Compound 22 was 
shown to inhibit weakly the isoforms CYP2C9, CYP2D6 and CYP3A4, with % of inhibition of 28.9, 
5.0 and 12.2, respectively, whereas the isoforms CYP1A2 and CYP2C19 were inhibited by 66.8% and 
72.6%, respectively (Table 5). 
 
CONCLUSIONS 
We synthesized 55 new pyrrole derivatives as potential anticancer agents, with the compounds 
having different substituents on the pendant 1-phenyl ring. Both the 1-phenyl ring and the 3-(3,4,5-
trimethoxyphenyl)carbonyl moieties were mandatory to achieve potent inhibition of tubulin 
polymerization and cancer cell growth. Several new 3-aroyl-1-arylpyrroles (ARAPs) inhibited tubulin 
polymerization with IC50 values in the 1.0-ȝ0FRQFHQWUDWLRQ UDQJH DQG ILYH FRPSRXQGV \LHOGHG
IC50 YDOXHV07ZHOYH$5$3VLQKLELWHGWKHJURZWKRIKXPDQ0&)-7 cells with IC50 YDOXHV
nM. ARAP 22 inhibited MCF-7 cell growth with an IC50 of 15 nM and was similar to 1 and VBL as an 
inhibitor of the growth of HeLa, HT-29 and A549 cells. Compound 22 or 27 strongly inhibited PC-3, 
RD and HepG2 cell growth as compared with PTX as reference compound. Furthermore, ARAP 27 
proved to be a more effective inhibitor of proliferation in PC-3 and HepG2 cells in comparison with the 
compounds used as reference agents. A 24 h treatment with either 22 or 27 induced a robust 
accumulation of cells in the G2/M phase of the cell cycle at 500 nM, and 27 also showed a dose-
dependent effect on PC-3 cell cycle progression. Beside the arrest of cell cycle progression, a strong 
induction of cell death was also detected in HeLa, PC-3, RD and HepG2 cells exposed to 22 or 27 for 
48 h. ARAP 22 showed strong inhibition of the Pgp-overexpressing NCI-ADR-RES and Messa/Dx5 
MDR cell lines. Against these MDR cell lines, 22 had activity similar to that of 2, while the reference 
agents 1, VRB, VBL and PTX showed very limited inhibition. Compounds 4 and 22 effectively 
arrested cell cycle progression at 100 nM, with the majority of cells accumulating in the G2/M phase in 
HeLa, PC-3, RD, and HepG2 cells. At 20 nM, 22 was as effective as VBL or 2. In addition, eight 
ARAPs caused a marked increase in the mitotic index in K562 leukemia cells, a hallmark of antitubulin 
agents. Compounds 22 and 27 suppressed in vitro the Hh signaling pathway, strongly reducing 
luciferase activity in SAG treated NIH3T3 Shh-Light II cells, and both compounds inhibited the growth 
of medulloblastoma D283 cells at nanomolar concentrations. Available data suggest that the anticancer 
activity of ARAP derivatives is due to strong inhibition of tubulin polymerization (IC50 <5 PM: 4, 9-13, 
18-26, 29-35 and 38-45) and of the Hedgehog signaling pathway (18 and 23). However, it should be 
noted that the overall observed cellular responses may be due as well WR ³RII-WDUJHW HIIHFWV´ not 
necessarily involving the above targets. 
ARAP 22 showed high Caco-2 cell permeability, inhibited weakly the human cloned P450 
isoforms CYP2C9, CYP2D6 and CYP3A4 and showed significant inhibition of CYP1A2 and 
CYP2C19. The isoform CYP1A2 is thought to be procarcinogenic; therefore, its inhibition may lead to 
a cancer-chemopreventive effect. In pharmacokinetics studies, ARAP 22 showed a long half-life, a 
rapid clearance and therefore a large volume of distribution, and a good oral bioavailability in the 
mouse. This is still a suboptimal pharmacokinetic profile, however, considering its very attractive cell 
growth inhibition profile, ARAP 22 represents an important lead compound for further in vivo proof-
of-concept studies. 
In short, ARAPs are a new potent class of tubulin polymerization and cancer cell growth 
inhibitors that have also the potential to inhibit strongly the Hh signaling pathway. Compounds 22 and 
27 represent novel lead compounds of the ARAP class that pave the way for the development of new 
promising anticancer agents, including possible activity against Hh-dependent cancers. 
 
EXPERIMENTAL SECTION 
Chemistry. MW-assisted reactions were performed on a CEM Discover SP single mode reactor, 
controlling the reaction parameters and instrument settings with PC-running CEM Synergy 1.49 
software. Closed vessel experiments were carried out in capped MW-dedicated vials (10 mL) with 
cylindrical stirring bar (length 8 mm, diameter 3 mm). Open vessel experiments were carried out in 100 
mL round-bottom flasks equipped with a Dimroth reflux condenser and a cylindrical stirring bar 
(length 20 mm, diameter 6 mm). Stirring, temperature, irradiation power, maximum pressure (Pmax), 
PowerMAX (simultaneous cooling-while-heating), ActiVent (simultaneous venting-while-heating), and 
ramp and hold times were set as indicated. Temperature of the reaction was monitored by an external 
fiber optic temperature sensor. After completion of the reaction, the mixture was cooled to 25 °C via 
air-jet cooling. Melting points (mp) were determined on a Stuart Scientific SMP1 apparatus and are 
uncorrected. Infrared spectra (IR) were run on a Perkin-Elmer SpectrumOne FT-ATR 
spectrophotometer. Band position and absorption ranges are given in cm-1. Proton nuclear magnetic 
resonance (1H NMR) spectra were recorded on a Bruker 400 MHz FT spectrometer in the indicated 
solvent and corresponding fid files processed by MestreLab Research S.L. MestreReNova 6.2.1-769 
software. Chemical shifts are expressed in į XQLWV SSP IURP WHWUDPHWK\OVLODQH &ROXPQ
FKURPDWRJUDSK\ZDVSHUIRUPHGRQFROXPQVSDFNHGZLWKDOXPLQDIURP0HUFNíPHVKRUVLOLFD
gel from Macherey-Nagel (70-230 mesh). Aluminum oxide thin layer chromatography (TLC) cards 
from Fluka (aluminum oxide precoated aluminum cards with fluorescent indicator visualizable at 254 
nm) and silica gel TLC cards from Macherey-Nagel (silica gel precoated aluminum cards with 
fluorescent indicator visualizable at 254 nm) were used for TLC. Developed plates were visualized 
with a Spectroline ENF 260C/FE UV apparatus. Organic solutions were dried over anhydrous Na2SO4. 
Evaporation of the solvents was carried out on a Büchi Rotavapor R-210 equipped with a Büchi V-850 
vacuum controller and a Büchi V-700 or V-710 vacuum pump. All reagents and solvents are 
commercially available and were used as purchased, without further purification. Elemental analyses of 
the compounds were found to be within ±0.4% of the theoretical values. The purity of tested 
compounds was found to be >95% by high pressure liquid chromatography (HPLC) analysis. The 
HPLC system used (Dionex UltiMate 3000, Thermo Fisher Scientific Inc.) consisted of a SR-3000 
solvent rack, a LPG-3400SD quaternary analytical pump, a TCC-3000SD column compartment, a 
DAD-3000 diode array detector and an analytical manual injection valve with a 20 PL loop. Samples 
were dissolved in acetonitrile at 10 mg/mL. HPLC analysis was performed by using an Acclaim 120 
C18 reversed-phase column (5 Pm, 4.6 x 250 mm, Thermo Fisher Scientific Inc.) at 30 ± 1 °C with  an 
isocratic gradient (acetonitrile:water = 90:10), flow rate of 1.0 mL/min and signal detector at 254 nm 
and 365 nm. Chromatographic data were acquired and processed by Chromeleon 6.80 software 
(Thermo Fisher Scientific Inc.). As an example, the HPLC analysis of compound 4 is shown in the 
Supporting Information. 
General Procedure for the Preparation of Compounds 4, 10-20, 32-41, 45 and 47-60. Example: 
(1-Phenyl-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (4) and (1-phenyl-1H-pyrrol-2-yl)(3,4,5-
trimethoxyphenyl)methanone (56). A mixture of anhydrous AlCl3 (0.17 g, 0.0013 mol), 1-phenyl-1H-
pyrrole (0.19 g, 0.0013 mol) and 3,4,5-trimethoxybenzoyl chloride (0.30 g, 0.0013 mol) in anhydrous 
1,2-dichloroethane (2.0 mL) was placed into the MW cavity (closed vessel mode, Pmax = 250 psi). A 
starting MW irradiation of 150 W was used, the temperature being ramped from 25 to 110 °C while 
stirring vigorously. Once 110 °C was reached, taking about 1 min, the reaction mixture was held at this 
temperature for 2 min. After cooling, the mixture was diluted with water, made acidic with 1 N HCl 
and extracted with chloroform. The organic layer was washed with brine, dried and filtered. Removal 
of the solvent gave a residue that was purified by column chromatography (silica gel, ethyl acetate:n-
hexane = 1:1 as eluent) to give 56 (0.18 g, 42%), mp 120-125 °C (from ethanol/n-hexane). 1H NMR 
(CDCl3): G 3.92 (s, 6H), 3.95 (s, 3H), 6.37-6.39 (m, 1H), 6.96-6.98 (m, 1H), 7.16-7.17 (m, 1H), 7.22 (s, 
2H), 7.33-7.35 (m, 2H), 7.39-7.47 ppm (m, 3H). IR: Q 1637 cm-1. Anal. (C20H19NO4 (337.37)) C, H, N. 
Further elution with the same eluent furnished 4 (0.19 g, 43%), mp 88-90 °C (from ethanol/n-hexane). 
1H NMR (CDCl3): G 3.94 (s, 6H), 3.96 (s, 3H), 6.89-6.90 (m, 1H), 7.14-7.16 (m, 1H), 7.19 (s, 2H), 
7.36-7.40 (m, 1H), 7.44-7.46 (m, 2H), 7.49-7.51 (m, 2H), 7.67-7.69 ppm (m, 1H). IR: Q 1621 cm-1. 
Anal. (C20H19NO4 (337.37)) C, H, N. 
(1-Methyl-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (10). Obtained as 4 from 1-methyl-
1H-pyrrole. Yield 16%, mp 130-135 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.30 (s, 3H), 
3.93 (s, 6H), 3.94 (s, 3H), 6.66-6.68 (m, 1H), 6.69-6.71 (m, 1H), 7.13 (s, 2H), 7.25-7.27 ppm (m, 1H). 
IR: Q 1610 cm-1. Anal. (C15H17NO4 (275.30)) C, H, N. 
Phenyl(1-phenyl-1H-pyrrol-3-yl)methanone (11). Obtained as 4 from 1-phenyl-H-pyrrole. Yield 
29%. 1H NMR (CDCl3): G 6.89-6.91 (m, 1H), 7.11 7.13 (m, 1H), 7.32-7.36 (m, 1H), 7.41-7.49 (m, 6H), 
7.51-7.53 (m, 1H), 7.61-7.64 (m, 1H), 7.89-7.93 ppm (m, 2H). IR: Q 1630 cm-1.22 
(1-(2-Chlorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (12). Obtained as 4 from 
63. Yield 10%, mp 115-117 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.93 (s, 6H), 3.94 (s, 3H), 
6.90-6.91 (m, 1H), 6.94-6.95 (m, 1H), 7.21 (s, 2H), 7.39-7.41 (m, 3H), 7.49-7.51 (m, 1H), 7.56-7.59 
ppm (m, 1H). IR: Q 1633 cm-1. Anal. (C20H18ClNO4 (371.81)) C, H, Cl, N. 
(1-(3-Chlorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (13). Obtained as 4 from 
64. Yield 16%, mp 110-115 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.94 (s, 6H), 3.95 (s, 3H), 
6.88-6.89 (m, 1H), 7.12 (dd, J = 2.3 and 3.1 Hz, 1H), 7.18 (s, 2H), 7.33-7.36 (m, 2H), 7.41-7.46 (m, 
2H), 7.65-7.66 ppm (m, 1H). IR: Q 1616 cm-1. Anal. (C20H18ClNO4 (371.81)) C, H, Cl, N. 
(1-(4-Chlorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (14). Obtained as 4 from 1-
(4-chlorophenyl)-1H-pyrrole. Yield 14%, mp 125-128 °C (from ethanol/n-hexane). 1H NMR (CDCl3): 
G 3.94 (s, 6H), 3.95 (S, 3H), 6.8-6.88 (m, 1H), 7.00 (t, J = 2.7 Hz, 1H), 7.20 (s, 2H), 7.37-7.40 (m, 2H), 
7.45-7.49 (m, 2H), 7.64 ppm (t, J = 2.1 Hz, 1H). IR: Q 1636 cm-1. Anal. (C20H18ClNO4 (371.81)) C, H, 
Cl, N. 
(1-(2-Fluorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (15). Obtained as 4 from 1-
(2-fluorophenyl)-1H-pyrrole. Yield 54%, mp 119-121 °C (from ethanol/n-hexane). 1H NMR (DMSO-
d6): G3.76 (s, 3H), 3.86 (s, 6H), 6.80-6.81 (m, 1H), 7.14 (s, 2H), 7.32-7.39 (m, 2H), 7.46-7.51 (m, 2H), 
7.70 (t, J = 7.8 Hz, 1H), 7.84-7.85 ppm (m, 1H). IR: Q 1633 cm-1. Anal. (C20H18FNO4 (355.36)) C, H, F, 
N. 
(1-(3-Fluorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (16). Obtained as 4 from 1-
(3-fluorophenyl)-1H-pyrrole. Yield 70%, mp 107-114 °C (from ethanol/n-hexane). 1H NMR (DMSO-
d6): G 3.77 (s, 3H), 3.87 (s, 6H), 6.80-6.82 (m, 1H), 7.14 (s, 2H), 7.16-7.21 (m, 1H), 7.51-7.57 (m, 1H), 
7.61-7.63 (m, 2H), 7.71-7.75 (m, 1H), 8.13-8.15 ppm (m, 1H). IR: Q 1706 cm-1. Anal. (C20H18FNO4 
(355.36)) C, H, F, N. 
(1-(4-Fluorophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (17). Obtained as 4 from 1-
(4-fluorophenyl)-1H-pyrrole. Yield 54%, mp 140-144 °C (from ethanol/n-hexane). 1H NMR (DMSO-
d6): G3.76 (s, 3H), 3.86 (s, 6H), 6.78-6.79 (m, 1H), 7.13 (s, 2H), 7.36 (t, J = 2.6 Hz, 2H), 7.50-7.52 (m, 
1H), 7.76-7.79 (m, 2H), 8.00-8.02 ppm (m, 1H). IR: Q 1634 cm-1. Anal. (C20H18FNO4 (355.36)) C, H, F, 
N. 
(1-(2-Nitrophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (18). Obtained as 4 from 1-
(2-nitrophenyl)-1H-pyrrole. Yield 40%, mp 150-155 °C (from ethanol/n-hexane). 1H NMR (DMSO-
d6): G 3.75 (s, 3H), 3.86 (s, 6H), 6.78-6.79 (m, 1H), 7.09 (s, 2H), 7.20-7.21 (m, 1H), 7.70-7.79 (m, 3H), 
7.86-7.91 (m, 1H), 8.17 ppm (dd, J = 1.4 and 8.2 Hz, 1H). IR: Q 1635 cm-1. Anal. (C20H18N2O6 
(382.37)) C, H, N. 
(1-(3-Nitrophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (19). Obtained as 4 from 65. 
Yield 46%, mp 145-150 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.78 (s, 3H), 3.87 (s, 6H), 
6.84-6.85 (m, 1H), 7.16 (s, 2H), 7.72-7.73 (m, 1H), 7.80 (t, J = 8.2 Hz, 1H), 8.17-8.26 (m, 3H), 8.53-
8.54 ppm (m, 1H). IR: Q 1640 cm-1. Anal. (C20H18N2O6 (382.37)) C, H, N. 
(1-(4-Nitrophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (20). Obtained as 4 from 1-
(4-nitrophenyl)-1H-pyrrole. Yield 68%, mp 175-185 °C (from ethanol/n-hexane). 1H NMR (DMSO-
d6): G3.78 (s, 3H), 3.88 (s, 6H), 6.87-6.88 (m, 1H), 7.15 (s, 2H), 7.76-7.77 (m, 1H), 8.07 (d, J = 9.2 Hz, 
2H), 8.25-8.26 (m, 1H), 8.34 ppm (d, J = 9.2 Hz, 2H). IR: Q 1633 cm-1. Anal. (C20H18N2O6 (382.37)) C, 
H, N. 
(1-(2-Tolyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (32). Obtained as 4 from 66. Yield 
71%, mp 120-125 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G2.24 (s, 3H), 3.75 (s, 3H), 3.82 
(s, 6H), 6.74-6.76 (m, 1H), 7.12-7.14 (m, 3H), 7.35-7.43 (m, 4H), 7.64-7.66 ppm (m, 1H). IR: Q 1632 
cm-1. Anal. (C21H21NO4 (351.40)) C, H, N. 
(1-(3-Tolyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (33). Obtained as 4 from 67. Yield 
80%, mp 105-109 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 1.28 (s, 3H), 130 (s, 3H), 3.77 
(s, 3H), 3.86 (s, 6H), 4.73-7.81 (m, 1H), 6.77 (s, 1H), 6.89 (d, J = 7.3 Hz, 1H), 7.14 (s, 2H), 7.23-7.25 
(m, 2H), 7.34-7.38 (m, 1H), 7.55 (s, 1H), 8.06 ppm (s, 1H). IR: Q 1712 cm-1. Anal. (C23H25NO5 
(395.45)) C, H, N. 
(1-(4-Tolyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (34). Obtained as 4 from 68. Yield 
62%, mp 100-105 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G2.35 (s, 3H), 3.76 (s, 3H), 3.86 
(s, 6H), 6.77-6.78 (m, 1H), 7.13 (s, 2H), 7.30 (d, J = 8.2 Hz, 2H), 7.50 (t, J = 2.8 Hz, 1H), 7.60 (d, J = 
8.4 Hz, 2H), 7.97-7.98 ppm (m, 1H). IR: Q 1632 cm-1. Anal. (C21H21NO4 (351.40)) C, H, N. 
(1-(2-Methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (35). Obtained as 4 from 
69. Yield 25%, mp 120-123 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.89 (s, 3H), 3.94 (S, 
9H), 6.85-6.87 (m, 1H), 7.01-7.02 (dd, J = 2.1 and 3.0 Hz, 1H), 7.06-7.09 (m, 2H), 7.20 (s, 2H), 7.33-
7.39 (m, 2H), 7.58 ppm (t, J = 2.0 Hz, 1H). IR: Q 1633 cm-1. Anal. (C21H21NO5 (367.40)) C, H, N. 
(1-(3-Methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (36). Obtained as 4 from 
70. Yield 10%. 1H NMR (DMSO-d6): G 3.77 (s, 3H), 3.84 (s, 3H), 3.86 (s, 6H), 6.78-6.79 (m, 1H), 
6.91-6.93 (m, 1H), 7.14 (s, 2H), 7.27-7.29 (m, 2H), 7.38-7.42 (m, 1H), 7.55-7.56 (m, 1H), 8.07 ppm (t, 
J = 2.1 Hz, 1H). IR: Q 1633 cm-1. Anal. (C21H21NO5 (367.40)) C, H, N. 
(1-(4-Methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (37). Obtained as 4 from 
1-(4-methoxyphenyl)-1H-pyrrole. Yield 58%, mp 140-145 °C (from ethanol/n-hexane). 1H NMR 
(DMSO-d6): G 3.76 (s, 3H), 3.81 (s, 3H), 3.86 (s, 6H), 6.76-6.77 (m, 1H), 7.03-7.07 (m, 2H), 7.13 (s, 
2H), 7.42-7.43 (m, 1H), 7.61-7.65 (m, 2H), 7.92-793 ppm (m, 1H). IR: Q 1632 cm-1. Anal. (C21H21NO5 
(367.40)) C, H, N. 
(1-(2-Isopropoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (38). Obtained as 4 
from 71. Yield 42%, mp 130-133 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G0.98 (s, 3H), 
0.99 (s, 3H), 3.77 (s, 3H), 3.82 (s, 6H), 4.40-4.46 (m, 1H), 6.36 (t, J = 3.2 Hz, 1H), 6.83-6.85 (m, 1H), 
7.11 (s, 2H), 7.21-7.27 (m, 2H), 7.37 (t, J = 7.7 Hz, 1H), 7.45 (d, J = 7.8 Hz, 1H), 7.70-7.072 ppm (m, 
1H). IR: Q 1618 cm-1. Anal. (C23H25NO5 (395.45)) C, H, N. 
(1-(3-Isopropoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (39). Obtained as 4 
from 72. Yield 35% as a slurry. 1H NMR (DMSO-d6): G 1.28 (s, 3H), 130 (s, 3H), 3.77 (s, 3H), 3.86 (s, 
6H), 4.73-7.81 (m, 1H), 6.77 (s, 1H), 6.89 d, J = 7.3 Hz, 1H), 7.14 (s, 2H), 7.23-7.25 (m, 2H), 7.34-
7.38 (m, 1H), 7.55 (s, 1H), 8.06 ppm (s, 1H). IR: Q 1634 cm-1. Anal. (C23H25NO5 (395.45)) C, H, N. 
(1-(4-Isopropoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (40). Obtained as 4 
from 73. Yield 63%, mp 99-100 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G1.28 (s, 3H), 1.29 
(s, 3H), 3.76 (s, 3H), 3.86 (s, 6H), 4.63-4.69 (m, 1H), 6.74-6.76 (m, 1H), 7.02 (d, J = 8.9 Hz, 2H), 7.13 
(s, 2H), 7.42-7.43 (m, 1H), 7.59 (d, J = 8.9 Hz, 2H), 7.90-7.92 ppm (m, 1H). IR: Q 1629 cm-1. Anal. 
(C23H25NO5 (395.45)) C, H, N. 
(1-(3-(Benzyloxy)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (41). Obtained as 4 
from 74. Yield 12% as a slurry. 1H NMR (DMSO-d6): G3.77 (s, 3H), 3.83 (s, 6H), 5.22 (s, 2H), 6.78-
6.79 (m, 1H), 7.00-7.02 (m, 1H), 7.14 (s, 2H), 7.31-7.36 (m, 2H), 7.39-743 (m, 4H), 7.48 (t, J = 7.2 Hz, 
2H), 7.55 (t, J = 2.6 Hz, 1H), 8.03-8.05 ppm (m, 1H). IR: Q 1633 cm-1. Anal. (C27H25NO5 (443.49)) C, 
H, N. 
(1-(4-Methoxy-3-nitrophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (45). Obtained as 
4 from 75. Yield 30%, mp 100-110 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.77 (s, 3H), 
3.86 (s, 6H), 3.97 (s, 3H), 6.80-6.81 (m, 1H), 7.13 (s, 2H), 7.48 (d, J = 9.2 Hz, 1H), 7.57-7.58 (m, 1H), 
8.05 (dd, J = 2.9 and 9.1 Hz, 1H), 8.10 (t, J = 1.9 Hz, 1H), 8.29 ppm (d, J = 2.9 Hz, 1H). IR: Q 1629 
cm-1. Anal. (C21H20N2O7 (412.39)) C, H, N. 
(1-(3-Hydroxy-4-methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (47). Obtained 
as 4 from 76. Yield 25%, mp 125-140 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.91 (s, 6H), 
3.92 (s, 3H), 3.94 (s, 3H), 5.80 (broad s, disappeared on treatment with D2O, 1H), 6.82-6.83 (m, 1H), 
6.89-6.91 (m, 2H), 7.00-7.03 (m, 2H), 7.15 (s, 2H), 7.55-7.56 ppm (m, 1H). IR: Q 1612, 2936, 3133 cm-
1
. Anal. (C21H21NO6 (383.39)) C, H, N. 
(1-(3,4-Dimethoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (48). Obtained as 4 
from 77. Yield 46%, mp 110-120 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.76 (s, 3H), 
3.80 (s, 3H), 3.85 (s, 3H), 3.86 (s, 6H), 6.75-6.77 (m, 1H), 7.04 (t, J = 8.8 Hz, 1H), 7.14 (s, 2H), 7.19 
(dd, J = 2.6 and 8.6 Hz, 1H), 7.26 (d, J = 2.6 Hz, 1H), 7.46-7.47 (m, 1H), 8.00-8.01 ppm (m, 1H). IR: Q 
1625 cm-1. Anal. (C22H23NO6 (397.42)) C, H, N. 
(1-(3-Isopropoxy-4-methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (49). 
Obtained as 4 from 76. Yield 33%, mp 95-100 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 1.36 
(s, 3H), 1.41 (s, 3H), 3.88 (s, 3H), 3.92 (s, 6H), 3.93 (s, 3H), 4.55-4.61 (m, 1H), 6.81-6.83 (m, 1H), 
6.92-6.98 (m, 3H), 7.01-7.03 (m, 1H), 7.17 (s, 2H), 7.57-7.58 ppm (m, 1H). IR: Q 1625 cm-1. Anal. 
(C24H27NO6 (425.47)) C, H, N. 
Phenyl(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl)methanone (50). Obtained as 4 from 78. Yield 
26%, mp 125-130 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.90 (s, 3H), 3.93 (s, 6H), 6.64 (s, 
2H), 6.86-6.88 (m, 1H), 7.06-7.08 (m, 1H), 7.49-7.53 (m, 2H), 7.57-7.61 (m, 2H), 7.90-7.93 ppm (m, 
2H). IR: Q 1638 cm-1. Anal. (C20H19NO4 (337.37)) C, H, N. 
(3,4,5-Trimethoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl)methanone (51). Obtained as 4 
from 78. Yield 23%, mp 95 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.90 (s, 3H), 3.93 (s, 6H), 
3.94 (s, 3H), 3.96 (s, 6H), 6.64 (s, 2H), 6.84-6.86 (m, 1H), 7.06-7.08 (m, 1H), 7.19 (s, 2H), 7.64-7.66 
ppm (m, 1H). IR: Q 1615 cm-1. Anal. (C23H25NO7 (337.37)) C, H, N. 
(3-Isopropoxy-4-methoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl)methanone (52). 
Obtained as 4 from 78 and 81. Yield 25%, mp 55-50 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 
3.89 (s, 3H), 3.90 (s, 6H), 3.97 (s, 3H), 5.75 (broad s, disappeared on treatment with D2O, 1H), 6.64 (s, 
2H), 6.84-6.85 (m, 1H), 6.95 (d, J = 8.2 Hz, 1H), 7.04-7.06 (m, 1H), 7.51-7.55 (m, 2H), 7.60-7.62 ppm 
(m, 1H). IR: Q 1600, 2933, 3133 cm-1. Anal. (C21H21NO6 (383.39)) C, H, N. 
(3-Isopropoxy-4-methoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl)methanone (53). 
Obtained as 4 from 78 and 81. Yield 45%, mp 140-145 °C (from ethanol/n-hexane). 1H NMR (CDCl3): 
G1.42 (s, 3H), 1.43 (s, 3H), 3.89 (s, 3H), 3.91 (s, 6H), 3.95 (s, 3H), 4.63-4.70 (m, 1H), 6.64 (s, 2H), 
6.83-6.84 (m, 1H), 6.96 (d, J = 8.4 Hz, 1H), 7.05-7.07 (m, 1H), 7.53-7.62 ppm (m, 3H). IR: Q 1627 cm-
1
. Anal. (C24H27NO6 (425.47)) C, H, N. 
(1-Benzyl-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (54). Obtained as 4 from 1-benzyl-
1H-pyrrole. Yield 17% as an oil. 1H NMR (CDCl3): G 3.88 (s, 6H), 3.93 (s, 3H), 5.12 (s, 2H), 6.74-6.76 
(m, 2H), 7.11 (s, 2H), 7.20-7.23 (m, 2H), 7.31-7.41 ppm (m, 4H). IR: Q 1628 cm-1. Anal. (C21H21NO4 
(351.40)) C, H, N. 
(1-(Phenylsulfonyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (55). Obtained as 4 from 1-
(phenylsulfonyl)-1H-pyrrole. Yield 64% as a slurry. 1H NMR (DMSO-d6): G 3.75 (s, 3H), 3.82 (s, 6H), 
6.78-6.80 (m, 1H), 7.04 (s, 2H), 7.53-7.55 (m, 1H), 7.66-7.70 (m, 2H), 7.78-7.82 (m, 1H), 7.97-7.99 (m, 
1H), 8.13-8.15 ppm (m, 2H). IR: Q 1637 cm-1. Anal. (C20H19NO6S (401.43)) C, H, N, S. 
(1-(3-Hydroxy-4-methoxyphenyl)-1H-pyrrol-2-yl)(3,4,5-trimethoxyphenyl)methanone (57) Obtained 
as 56 from 76. Yield 14%, mp 145-150 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.90 (s, 6H), 
3.92 (s, 3H), 3.96 (s, 3H), 5.83 (broad s, disappeared on treatment with D2O, 1H), 6.32-6.33 (m, 1H), 
6.81-6.92 (m, 4H), 7.09-7.11 (m, 1H), 7.20 ppm (s, 2H). IR: Q 1634, 2939, 3402 cm-1. Anal. 
(C21H21NO6 (383.39)) C, H, N. 
Phenyl(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2-yl)methanone (58). Obtained as 56 from 78. Yield 
10% as an oil. 1H NMR (CDCl3): G3.83 (s, 6H), 3.87 (s, 3H), 6.32-6.33 (m, 1H), 6.54 (s, 2H), 6.88 (dd, 
J = 1.7 and 4.0 Hz, 1H), 7.10-7.11 (m, 1H), 7.44-7.48 (m, 2H), 7.55-7.57 (m, 1H), 7.86-7.89 ppm (m, 
2H). IR: Q 1630 cm-1. Anal. (C20H19NO4 (337.37)) C, H, N. 
(3,4,5-Trimethoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2-yl)methanone (59). Obtained as 
56 from 78. Yield 13%, mp 130-135 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.86 (s, 6H), 
3.90 (s, 3H), 3.92 (s, 6H), 3.95 (s, 3H), 6.35-3.38 (m, 1H), 6.56 (s, 2H), 6.95-6.97 (m, 1H), 7.13-7.15 
(m, 1H), 7.20 ppm (s, 2H). IR: Q 1634 cm-1. Anal. (C23H25NO7 (337.37)) C, H, N. 
(3-Hydroxy-4-methoxyphenyl)(1-(3,4,5-trimethoxyphenyl)-1H-pyrrol-2-yl)methanone (60). Obtained 
as 16 from 78 and 81. Yield 25%, mp 140-147 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.84 
(s, 6H), 3.89 (s, 3H), 3.99 (S, 3H), 5.90 (broad s, disappeared on treatment with D2O, 1H), 6.33-6.34 
(m, 1H), 6.54 (s, 2H), 6.90-6.94 (m, 2H), 7.10-7.11 (m, 1H), 7.50-7.53 ppm (m, 2H). IR: Q 1623, 2921, 
3436 cm-1. Anal. (C21H21NO6 (383.39)) C, H, N. 
(1H-Pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (9). A solution of 55 (0.24 g, 0.6 mmol), 2 N 
NaOH (1.8 mL) and methanol (5.3 mL) was heated at reflux for 3 h. After cooling, the mixture was 
made acidic with 1 N HCl and extracted with ethyl acetate. The organic layer was washed with brine, 
dried and filtered. Removal of the solvent gave a residue that was purified by column chromatography 
(silica gel, ethyl aceate:n-hexane = 3:2 as eluent) to give 9 (0.13 g, 85%), mp 155-160 °C (from 
ethanol/n-hexane) 1H NMR (CDCl3): G 3.91 (s, 6H), 3.94 (s, 3H), 6.78-6.79 (m, 1H), 6.87-6.88 (m, 1H), 
7.15 (s, 2H), 7.42-7.43 (m, 1H), 8.88 ppm (broad s, disappeared on treatment with D2O, 1H). IR: Q 
1603, 3204 cm-1. Anal. (C14H15NO4 (261.27)) C, H, N. 
(4-Phenyl-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (61). A solution of 82 (0.50 g, 0.0017 
mol) and TosMIC (0.33 g, 0.0017 mol) in anhydrous DMSO/Et2O (1:2, 15.0 mL) was added dropwise 
to a well-stirred suspension of NaH (0.33 g, 0.0076 mol; 55% in mineral oil) in anhydrous Et2O under 
an Ar stream. The reaction mixture was stirred at 25 °C for 15 min, diluted with water and extracted 
with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent 
gave a residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as 
eluent) to furnish 61 (0.43 g, 75%), mp 190 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.81 (s, 
6H), 3.88 (s, 3H), 6.93 (m, 1H), 7.10 (s, 2H), 7.16-7.20 (m, 1H), 7.23-7.25 (m, 2H), 7.29-7.31 (m, 1H), 
7.33-7.36 (m, 2H), 8.83 ppm (broad s, disappeared on treatment with D2O, 1H). IR: Q 1605, 3247 cm-1. 
Anal. (C20H19NO4 (337.37)) C, H, N. 
Phenyl(4-(3,4,5-trimethoxyphenyl)-1H-pyrrol-3-yl)methanone (62). Synthesized as 61 from 83. 
Yield 38%, mp 180 °C (from ethanol/n-hexane). 1H NMR (CDCl3): G 3.81 (s, 6H), 3.84 (s, 3H), 6.64 (s, 
2H), 6.93-6.94 (m, 1H), 7.27-7.28 (m, 1H), 7.37 (t, J = 7.3 Hz, 2H), 7.48 (t, J = 8.0 Hz, 1H), 7.81-7.83 
(m, 2H), 8.81 ppm (broad s, disappeared on treatment with D2O, 1H). IR: Q 1617, 3285 cm-1. Anal. 
(C20H19NO4 (337.37)) C, H, N. 
General Procedure for the Preparation of Compounds 21-23 and 46. Example: (1-(2-
Aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (21). A mixture of 18 (0.2 g, 0.52 
mmol) and SnCl2Â2H2O (0.58 g, 0.0026 mol) in ethyl acetate was heated at reflux for 3 h. After cooling, 
the reaction mixture was made basic with a saturated aqueous solution of NaHCO3 and extracted with 
ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of the solvent gave 
a residue that was purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as 
eluent) to give 21 (0.12 g, 65%), mp 110-115 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.75 
(s, 3H), 3.85 (s, 6H), 5.11 (broad s, disappeared on treatment with D2O, 2H), 6.63-6.65 (m, 1H), 6.76-
6.77 (m, 1H), 6.87 (d, J = 7.04 Hz, 1H), 7.06 (t, J = 2.7 Hz, 1H), 7.10-7.12 (m, 2H), 7.17 (s, 2H), 7.55 
ppm (t, J = 1.8 Hz, 1H). IR: Q 1615, 2990, 3126, 3324, 3445 cm-1. Anal. (C20H20N2O4 (352.38)) C, H, 
N. 
(1-(3-Aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (22). Synthesized as 21 
from 19. Yield 60%, mp 160 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.76 (s, 3H), 3.86 (s, 
6H), 5.36 (broad s, disappeared on treatment with D2O, 2H), 6.53-6.56 (m, 1H), 6.75-6.80 (m, 3H), 
7.10-7.14 (m, 3H), 7.36-7.37 (m, 1H), 7.79 ppm (t, J = 1.9 Hz, 1H). IR: Q 1615, 2939, 3363 cm-1. Anal. 
(C20H20N2O4 (352.38)) C, H, N. 
(1-(4-Aminophenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (23). Synthesized as 21 
from 20. Yield 58%, mp 55-60 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G3.76 (s, 3H), 3.85 
(s, 6H), 5.26 (broad s, disappeared on treatment with D2O, 2H), 6.64 (d, J = 8.6 Hz, 2H), 6.70-6.72 (m, 
1H), 7.11 (s, 2H), 7.29-7.32 (m, 3H), 7.75-7.77 ppm (m, 1H). IR: Q 1639, 3367, 3461 cm-1. Anal. 
(C20H20N2O4 (352.38)) C, H, N. 
(1-(3-Amino-4-methoxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (46). 
Synthesized as 21 from 45. Yield 42%, mp 165-170 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): 
G 3.76 (s, 3H), 3.80 (s, 3H), 3.85 (s, 6H), 5.01 (broad s, disappeared on treatment with D2O, 2H), 6.73-
6.79 (m, 2H), 6.85-6.88 (m, 1H), 7.11 (s, 2H), 7.29 (dd, J = 2.2 and 3.0 Hz, 1H), 7.29 (dd, J = 2.2 and 
3.0 Hz, 1H), 7.72 ppm (t, J = 1.9 Hz, 1H). IR: Q 1617, 2959, 3360, 3458 cm-1. Anal. (C21H22N2O5 
(382.41)) C, H, N.  
General Procedure for the Preparation of Compounds 42-44. Example: (1-(2-Hydroxyphenyl)-
1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (42). A mixture of 38 (0.17 g, 0.43 mmol) and 
methanesulfonic acid (1.33 g, 0.9 mL; 0.014 mol) in chloroform (9.0 mL) was refluxed for 2.5 h under 
an Ar stream. After cooling, the mixture was poured into ice/water and extracted with chloroform. The 
organic layer was washed with brine, dried and filtered. Removal of the solvent gave a residue that was 
purified by column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to afford 42 
(0.04 g, 35%), mp 160 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G
66.71-6.73 (m, 1H), 6.93 (t, J = 7.4 Hz, 1H), 7.06 (d, J = 8.2 Hz, 1H), 7.14 (s, 2H), 7.20-7.23 (m, 2H), 
7.39 (d, J = 7.7 Hz, 1H), 7.76-7.78 (m, 1H), 9.94 ppm (broad s, disappeared on treatment with D2O, 
1H). IR: Q 1610, 3240 cm-1. Anal. (C20H19NO5 (353.37)) C, H, N. 
 (1-(3-Hydroxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (43). Synthesized as 42 
from 39. Yield 51%, mp 160-164 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G 3.77 (s, 3H), 
3.86 (s, 6H), 6.75-6.78 (m, 2H), 7.01-7.03 (m, 1H), 7.08-7.13 (m, 3H), 7.28 (t, J = 8.1 Hz, 1H), 7.43-
7.46 (m, 1H), 7.91 (s, 1H), 9.88 ppm (broad s, disappeared on treatment with D2O, 1H). IR: Q 1596, 
2619, 2937, 2988, 3136 cm-1. Anal. (C20H19NO5 (353.37)) C, H, N. 
 (1-(4-Hydroxyphenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (44). Synthesized as 42 
from 40. Yield 28%, mp 200-204 °C (from ethanol/n-hexane). 1H NMR (DMSO-d6): G
3.86 (s, 6H), 6.73-6.75 (m, 1H), 6.85 (d, J = 8.8 Hz, 2H), 7.12 (s, 2H), 7.36 (t, J = 2.4 Hz, 1H), 7.48 (d, 
J = 8.8 Hz, 2H), 7.82-7.84 (m, 1H), 9.73 ppm (broad s, disappeared on treatment with D2O, 1H). IR: Q 
1610, 3240 cm-1. Anal. (C20H19NO5 (353.37)) C, H, N. 
(1-(3-(Methylamino)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (24) and (1-(3-
(Dimethylamino)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (26). A mixture of 22 
(0.15 g, 0.43 mmol), dimethyl sulfate (0.054 g, 0.04 mL, 0.43 mmol) and Na2CO3 (0.12 g, 0.0011 mol) 
in anhydrous acetone (5.0 mL) was stirred at 25 °C for 16 h under an Ar stream. After dilution with 
water, the mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried and 
filtered. Removal of the solvent gave a residue that was purified by column chromatography (silica gel, 
ethyl acetate:n-hexane = 1:1 as eluent) to furnish 26 (0.05 g, 31%) as a slurry. 1H NMR (CDCl3): 
G3.01 (s, 6H), 3.92 (s, 6H), 3.94 (s, 3H), 6.68-6.70 (m, 2H), 6.72-6.75 (m, 1H), 6.84-6.86 (m, 1H), 
7.11-7.12 (m, 1H), 7.18 (s, 2H), 7.27-7.32 (m, 1H), 7.67 ppm (t, J = 1.8 Hz, 1H). IR: Q 1633 cm-1. Anal. 
(C22H24N2O4 (380.44)) C, H, N. Further elution with the same eluent furnished 24 (0.05 g, 31%) as a 
slurry. 1H NMR (DMSO-d6): G2.70 (s, 3H), 3.74 (s, 3H), 6.84 (s, 6H), 5.93 (broad s, disappeared after 
treatment with D2O, 1H), 6.51 (d, J = 8.6 Hz, 1H), 6.70-6.79 (m, 3H), 7.12 (s, 2H), 7.14-7.18 (m, 1H), 
7.42 (s, 1H), 7.89 ppm (s, 1H). IR: Q 1610, 3937, 3396 cm-1. Anal. (C21H22N2O4 (366.41)) C, H, N. 
 (1-(3-(Isopropylamino)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (25). NaCNBH3 
(0.053 g, 0.85 mmol) was added to an ice-cooled mixture of 22 (0.25 g, 0.7 mmol) and acetone (0.041 
g, 0.052 mL, 0.7 mmol) in methanol/THF (1:1, 8.9 mL) containing 6 N HCl/methanol (1:1, 0.12 mL). 
The reaction mixture was stirred at 25 °C for 12 h, made basic with a saturated aqueous solution of 
K2CO3 and extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. 
Removal of the solvent gave a residue that was purified by column chromatography (silica gel, ethyl 
acetate:n-hexane = 1:1 as eluent) to furnish 25 (0.16 g, 57%) as a slurry. 1H NMR (CDCl3): G1.24 (s, 
3H), 1.25 (s, 3H), 3.67-3.70 (m, 2H; one proton disappeared after treatment with D2O), 3.92 (s, 6H), 
3.93 (s, 3H), 6.52-6.58 (m, 2H), 6.67-6.71 (m, 1H), 6.83-6.84 (m, 1H), 7.08-7.10 (m, 1H), 7.17 (s, 2H), 
7.25 (t, J = 8.0 Hz, 1H), 7.63 ppm (t, J = 1.8 Hz, 1H). IR: Q 1610, 2965, 3368 cm-1. Anal. (C23H26N2O4 
(394.46)) C, H, N. 
1-(3-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)phenyl)guanidine hydrochloride (27). Cyanamide 
(0.18 g, 0.0044 mol) was added in small portions with stirring to a solution of 22 (0.25 g, 0.71 mmol) 
in ethanol (5.0 mL) containing 3.3 N HCl (0.29 mL). The reaction mixture was heated at 50 °C for 48 h 
and cooled at 0 °C. The resulting suspension was filtered and the solid collected to give 27 (0.14 g, 
45%), mp 196-200 °C (from ethanol). 1H NMR (DMSO-d6/D2O): G3.74 (s, 3H), 3.83 (s, 6H), 6.79 (s, 
1H), 7.05-7.10 (m, 3H), 7.33-7.45 (m, 4H), 7.91 ppm (s, 1H). IR: Q 1642, 2590, 2841, 3200 cm-1. Anal. 
(C21H22N2O4ÂHCl (430.08)) C, H, N. 
N-(3-(3-(3,4,5-Trimethoxybenzoyl)-1H-pyrrol-1-yl)phenyl)methanesulfonamide (28). To a solution 
of 22 (0.050 g, 0.14 mmol) and triethylamine (0.016 g, 0.02 mL, 0.16 mmol) in anhydrous THF (5.0 
mL) was added dropwise a solution of methansulfonyl chloride (0.018 g, 0.01 mL, 0.16 mmol) in the 
same solvent (5.0 mL). The reaction mixture was stirred at 25 °C for 2 h, diluted with water and 
extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal of 
the solvent gave a residue that was purified by column chromatography (silica gel, chloroform:ethanol 
= 97:3 as eluent) to furnish 28 (0.03 g, 49%) as an oil. 1H NMR (CDCl3): G 3.00 (s, 3H), 3.93 (s, 6H), 
3.95 (s, 3H), 6.86-688 (m, 1H), 7.11 (t, J = 2.7 Hz, 1H), 7.19 (s, 2H), 7.21-7.28 (m, 3H), 7.42-7.49 (m, 
2H; one proton disappeared after treatment with D2O), 7.69 ppm (t, J = 1.8 Hz, 1H). IR: Q 1606, 2853, 
2924, 3237 cm-1. Anal. (C21H22N2O5 (382.41)) C, H, N. 
General Procedure for the Preparation of compounds 29, 63-78. Example: (1-(3-(1H-Pyrrol-1-
yl)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (29). A mixture of 22 (0.25 g, 0.7 
mmol) and 2,5-dimethoxytetrahydrofuran (0.092 g, 0.09 mL, 0.7 mmol) in glacial acetic acid (0.19 
mL) was heated at 80 °C for 2 h. After cooling, the solvent was evaporated, and the residue was made 
basic with a saturated aqueous solution of NaHCO3 and extracted with ethyl acetate. The organic layer 
was washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:2 as eluent) to furnish 29 (0.23 g, 82%) 
as an oil. 1H NMR (DMSO-d6): G3.77 (s, 3H), 3.83 (s, 6H), 6.29-6.31 (m, 2H), 6.80-6.82 (m, 1H), 7.16 
(s, 2H), 7.56-7.60 (m, 5H), 7.66-7.68 (m, 1H), 7.89-7.91 (m, 1H), 8.22-8.24 ppm (m, 1H). IR: Q 1632 
cm-1. Anal. (C24H22N2O4 (402.44)) C, H, N. 
1-(2-Chlorophenyl)-1H-pyrrole (63). Synthesized as 29 from 2-chloroaniline. Yield 72% as an oil.23 
1-(3-Chlorophenyl)-1H-pyrrole (64). Synthesized as 29 from 3-chloroaniline. Yield 72%, mp 50-
51 °C (from petroleum ether). Lit.24 50.5-51.5 °C. 
1-(3-Nitrophenyl)-1H-pyrrole (65). Synthesized as 29 from 3-nitroaniline. Yield 72%, mp 72-73 °C 
(from petroleum ether). Lit.24 75-76 °C  
1-(2-Tolyl)-1H-pyrrole (66). Synthesized as 29 from o-toluidine. Yield 46% as an oil. Lit.24 
1-(3-Tolyl)-1H-pyrrole (67). Synthesized as 29 from m-toluidine. Yield 54% as an oil. Lit.24 
1-(4-Tolyl)-1H-pyrrole (68). Synthesized as 29 from p-toluidine. Yield 55%, mp 80-81 °C (from 
ethanol). Lit.24 82.5-83.5 °C. 
1-(2-Methoxyphenyl)-1H-pyrrole (69). Synthesized as 29 from 2-methoxyaniline. Yield 40% as an 
oil. Lit.25 
1-(3-Methoxyphenyl)-1H-pyrrole (70). Synthesized as 29 from 3-methoxyaniline. Yield 48% as an 
oil. Lit.24 
1-(2-Isopropoxyphenyl)-1H-pyrrole (71). Synthesized as 29 from 2-isopropoxyaniline. Yield 50% as 
an oil. 1H NMR (DMSO-d6): G.22 (s, 3H), 1.24 (s, 3H), 5.52-4.58 (m, 1H), 6.17-6.19 (m, 2H), 7.00-
7.07 (m, 3H), 7.19 (d, J = 7.4 Hz, 1H), 7.25-7.33 ppm (m, 2H). 
1-(3-Isopropoxyphenyl)-1H-pyrrole (72). Synthesized as 29 from 3-isopropoxyaniline. Yield 38% as 
an oil. 1H NMR (DMSO-d6): G1.63 (s, 3H), 1.65 (s, 3H), 5.04-5.10 (m, 1H), 6.58-6.60 (m, 2H), 7.14 
(dd, J = 2.0 and 8.3 Hz, 1H), 7.43-7.46 (m, 2H), 7.66-7.72 ppm (m, 3H). 
1-(4-Isopropoxyphenyl)-1H-pyrrole (73). Synthesized as 29 from 4-isopropoxyaniline. Yield 53% as 
an oil. 1H NMR (DMSO-d6): G1.27 (s, 3H); 1.28 (s, 3H), 4.57-4.66 (m, 1H), 6.22 (t, J = 2.1 Hz, 2H), 
6.97-7.00 (m, 2H), 7.22 (t, J = 2.1 Hz, 2H), 7.43-7.46 ppm (m, 2H). 
1-(3-(Benzyloxy)phenyl)-1H-pyrrole (74). Synthesized as 29 from 3-benzyloxyaniline. Yield 34%, 
mp 40 °C (from toluene). 1H NMR (DMSO-d6): G5.19 (s, 2H), 6.26 (t, J = 2.2 Hz, 2H), 6.90 (dd, J = 
2.2 and 8.2 Hz, 1H), 7.14-7.16 (m, 1H), 7.22 (t, J = 2.2 Hz, 1H), 7.33-7.43 (m, 6H), 7.47-7.49 ppm (m, 
2H). 
1-(4-Methoxy-3-nitrophenyl)-1H-pyrrole (75). Synthesized as 29 from 4-methoxy-3-nitroaniline. 
Yield 73%, mp 80 °C (from toluene). 1H NMR (DMSO-d6): G3.96 (s, 3H), 6.28 (t, J = 2.2 Hz, 2H), 
7.40 (t, J = 2.2 Hz, 2H), 7.44 (d, J = 9.2 Hz, 1H), 7.89 (dd, J = 2.89 and 9.1 Hz, 1H), 8.10 ppm (d, J = 
2.9 Hz, 1H). 
1-(3-Isopropoxy-4-methoxyphenyl)-1H-pyrrole (76). Synthesized as 29 from 3-isopropoxy-4-
methoxyaniline. Yield 75%, mp 35-37 °C (from petroleum ether). 1H NMR (CDCl3): G1.40 (s, 3H), 
1.42 (s, 3H), 3.90 (s, 3H), 4.55-4.63 (m, 1H), 6.33-6.36 (m, 2H), 6.91-7.01 (m, 3H), 7.27-7.28 ppm (m, 
2H). 
1-(3,4-Dimethoxyphenyl)-1H-pyrrole (77). Synthesized as 29 from 3,4-dimethoxyaniline. Yield 50%, 
mp 60 °C (from petroleum ether). Lit.26 
1-(3-Isopropoxy-4-methoxyphenyl)-1H-pyrrole (78). Synthesized as 29 from 1-(3,4,5-
trimethoxyphenyl)-1H-pyrrole. Yield 55%, mp 89-91 °C (from toluene). 1H NMR (DMSO-d6): G3.64 
(s, 3H), 3.84 (s, 6H), 6.23 (s, 2H), 6.80 (s, 2H), 7.35 ppm (s, 2H). 
(1-(3-(Pyrrolidin-1-yl)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (30). A mixture 
of 22 (0.10 g, 0.28 mmol), 1,4-dibromobutane (0.065 g, 0.03 mL, 0.3 mmol) and K2CO3 (0.042 g, 0.3 
mmol) in water (1.0 mL) was placed into the MW cavity (closed vessel mode, Pmax = 250 psi). A 
starting MW irradiation of 100 W was used, the temperature being ramped from 25 to 110 °C while 
stirring rapidly. Once 110 °C was reached, taking about 1 min, the reaction mixture was held at this 
temperature for 20 min, diluted with water and extracted with ethyl acetate. The organic layer was 
washed with brine, dried and filtered. Removal of the solvent gave a residue that was purified by 
column chromatography (silica gel, ethyl acetate:n-hexane = 1:1 as eluent) to afford 30 (0.04 g, 35%) 
as a slurry. 1H NMR (CDCl3): G2.03-2.06 (m, 4H), 3.31-3.34 (m, 4H), 3.93 (s, 6H), 3.94 (s, 3H), 6.52-
6.54 (m, 2H), 6.66-6.68 (m, 1H), 6.83-6.85 (m, 1H), 7.11-7.13 (m, 1H), 7.18 (s, 2H), 7.26-7.30 (m, 1H), 
7.67 ppm (t, J = 2.0 Hz, 1H). IR: Q 1631 cm-1. Anal. (C24H26N2O4 (406.47)) C, H, N. 
(1-(3-(Piperidin-1-yl)phenyl)-1H-pyrrol-3-yl)(3,4,5-trimethoxyphenyl)methanone (31). Synthesized 
as 30 from 1,5-dibrompentane. Yield 57% as a slurry. 1H NMR (CDCl3): G1.59-1.65 (m, 2H), 1.69-
1.75 (m, 4H), 3.23-3.25 (m, 4H), 3.93 (s, 6H), 3.94 (s, 3H), 6.82-6.85 (m, 2H), 6.88-6.92 (m, 2H), 
7.09-7.10 (m, 1H), 7.17 (s, 2H), 7.31 (t, J = 8.0 Hz, 1H), 7.65 ppm (t, J = 2.0 Hz, 1H). IR: Q 1627 cm-1. 
Anal. (C25H28N2O4 (420.50)) C, H, N. 
Methyl 3-isopropoxy-4-methoxybenzoate (79). A mixture of methyl 3-hydroxy-4-methoxybenzoate 
(0.5 g, 0.0027 mol), anhydrous K2CO3 and 2-iodopropane (1.04 g, 0.61 mL, 0,0061 mol) in anhydrous 
DMF was heated at 50 °C for 3 h under an Ar stream. After cooling, the mixture was diluted with water 
and extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. Removal 
of the solvent gave a residue that was purified by column chromatography (silica gel, ethyl acetate:n-
hexane = 1:1) to furnish 79 (0.47 g, 76%), mp 50-55 °C (from ethanol/n-hexane). 1H NMR (CDCl3): 
G -4.64 (m, 1H), 6.88 (d, J = 8.5 Hz, 1H), 
7.56 (d, J = 2.0 Hz, 1H), 7.65 ppm (dd, J = 2.0 and 8.4 Hz, 1H). IR: Q 1710 cm-1. 
3-Isopropoxy-4-methoxybenzoic acid (80). A mixture of 79 (1.57 g, 0.0070 mol) and LiOHͼH2O in 
THF/H2O (1:1, 70 mL) was stirred at 25 °C for 12 h. The reaction mixture was made acidic with 1 N 
HCl and extracted with ethyl acetate. The organic layer was washed with brine, dried and filtered. 
Removal of the solvent gave a residue that was purified by column chromatography (silica gel, ethyl 
acetate:n-hexane = 1:1 as eluent) to furnish  80  (1.14 g, 77%), mp 130-135 °C (from ethanol). Lit.27 
3-Isopropoxy-4-methoxybenzoyl chloride (81). A mixture of 80 (1.0, 0.0052 mol) and SOCl2 (0.74 g, 
0.46 mL, 0.0062 mol) was heated at reflux for 1.5 h under an Ar stream. Evaporation of the excess of 
SOCl2 left crude 77, which was used without further purification. 
General Procedure for the Preparation of Compounds 82 and 83. Example: 3-Phenyl-1-(3,4,5-
trimethoxyphenyl)-trans-prop-2-en-1-one (82). A mixture of 1-(3,4,5-trimethoxyphenyl)ethanone (1.0 
g, 0.0048 mol), benzaldehyde (0.51 g, 0.49 mL, 0.0048 mol) and NaOH (0.19 g, 0.0048 mol) in ethanol 
(19.2 mL) was stirred at 25 °C for 24 h. After filtering, the resulting solid was collected to provide 82 
(0.58 g, 41%), mp 78-80 °C (from ethanol/n-hexane). Lit.28 
1-Phenyl-3-(3,4,5-trimethoxyphenyl)-trans-prop-2-en-1-one (83). Synthesized as 82 from 3,4,5-
trimethoxybenzaldehyde and acetophenone. Yield 67%, mp 130-135 °C (from ethanol/n-hexane), Lit.29 
135-136 °C. 
 Molecular Modeling. All molecular modeling studies were performed on a MacPro dual 2.66 GHz 
Xeon running Ubuntu 12.04 LTS. The tubulin structure was downloaded from the PDB code 3HKD.13 
Hydrogen atoms were added to the protein, using Molecular Operating Environment (MOE) 2010,30 
and the structures were energy minimized, keeping all the heavy atoms fixed until a rmsd gradient of 
0.05 kcal mol-1 Å-1 was reached. Ligand structures were built with MOE and minimized using the MM- 
FF94x forcefield until a rmsd gradient of 0.05 kcal mol-1 Å-1 was reached. The Smo structure (PDB 
code 4JKV)31 was prepared in the same manner. The docking simulations were performed using 
Glide,32 Plants33 and Autodock4.0.34 The pharmacophore model was created by the Pharmacophore 
query editor of MOE. The images presented here were created with Pymol.35 
 
Biology. Tubulin Assembly. The reaction mixtures contained 0.8 M monosodium glutamate 
S+  ZLWK +&O LQ D  0 VWRFN VROXWLRQ  ȝ0 WXEXOLQ DQG YDU\LQJ concentrations of drug. 
Following a 15 min preincubation at 30 °C, samples were chilled on ice, GTP to 0.4 mM was added, 
and turbidity development was followed at 350 nm in a temperature controlled recording 
spectrophotometer for 20 min at 30 °C. Extent of reaction was measured. Full experimental details 
were previously reported.36 
[3H]Colchicine Binding Assay. 7KH UHDFWLRQ PL[WXUHV FRQWDLQHG  ȝ0 WXEXOLQ  ȝ0
[3+@FROFKLFLQH DQG  ȝ0 LQKLELWRU DQG ZHUH LQFXEDWHG  PLQ DW  & &RPSOHWH GHWDLOV ZHUe 
described previously.37 
Cell Cultures. Cell lines were obtained from the American Tissue Culture Collection (ATCC), 
unless otherwise specified &HOOV ZHUH JURZQ LQ 'XOEHFFR¶V PRGLILHG (DJOH PHGLXP (DMEM) 
supplemented with 10% fetal bovine serum (FBS) at 37 °C with 5% CO2. In all experiments, 3x105 
cells were plated in 9 cm2 dishes and treated with a solution of test compound in DMSO (0.1% final 
concentration) at the indicated concentrations. HeLa, HT-29, and A549 cells were grown at 37 °C in 
DMEM containing 10 mM glucose supplemented with 10% FBS, 100 units/mL of penicillin and 
streptomycin, and 2 mM glutamine. At the onset of each experiment, cells were placed in fresh medium 
and cultured in the presence of test compound at 0.01- ȝ0 HCT116, HCT15, Messa, and 
Messa/Dx5 were seeded into 96-well plates (Corning Inc., Costar) at a density of 2x103 cells/well in a 
YROXPHRIȝ/RI WKH DSSURSULDWH WLVVXH FXOWXUHPHGLXP Test compounds were added at different 
concentrations for the indicated incubation time at 37 °C in the presence of 5% CO2. The MCF-7/cas-3 
cell line reconstituted with caspase-3 was a kind gift from Dr. Christopher J. Froelich (North Shore 
University, Health Systems Research Institute, Evanston, IL, USA). PC-3 cells were grown in DMEM 
containing 4.5 g/L of glucose, supplemented with 10% FBS, 100 units/mL of penicillin and 
streptomycin and 2 mM glutamine. RD and HepG2 cells were grown in DMEM containing 1 g/L of 
glucose supplemented with 10% FBS, 100 units/mL of penicillin and streptomycin, 2 mM glutamine 
and pyruvate. 
Cell Viability Assays. The methodology for the evaluation of the growth of human MCF-7 
breast carcinoma, OVCAR-8, and NCI/ADR-RES cells, obtained from the National Cancer Institute 
drug screening laboratory, was previously described, except that cells were grown for 96 h for IC50 
determinations.38 The drug screening laboratory also supplied the K562 cells, which were grown in 
suspension culture in the same medium as the other cell lines. They were grown in 5 mL of medium for 
20 h. For IC50 determinations, cell number was the parameter quantitated, using a Beckman Coulter 
model Z-1 Coulter particle counter. For MI studies, cells were harvested by centrifugation (2000 rpm 
for 2 min for all centrifugations). The cells were washed in 10 mL of PBS and harvested by 
centrifugation. Each pellet was suspended in 0.5 mL of ice-cold half-strength PBS for 13 min 
(hypotonic solution to cause cells to swell to make nuclear morphology easier to evaluate), following 
which 15 mL of 0.5% ethanol-1.5% acetic acid was added to each tube to fix the cells. After at least 30 
min, the cells were harvested by centrifugation. Each pellet was suspended in 0.5 mL of 75% ethanol-
25% acetic acid. One drop of each suspension was placed on separate microscope slides. The slides 
were air died, stained with Giemsa for 10 min, washed with water, air dried again and examined under 
a light microscope. At least 100 cells were counted for each data point. 
Cell viability of Hela, HT-29, and A549 cells was determined using the MTT colorimetric assay, 
whereby the mitochondrial dehydrogenase in viable cells transforms the yellow MTT reagent into a 
soluble blue formazan dye. Cells were seeded into 96-well plates to a density of 7x103ȝ/ZHOO
After 24 h of growth to allow attachment of cells to the wells, test compounds were added at 0.01-25 
ȝ0. After 48 h of growth and removal of the FXOWXUH PHGLXP  ȝ/ZHOO PHGLXP FRQWDLQLQJ 
mg/mL MTT was added. Cell cultures were further incubated at 37 °C for 2 h in the dark. The solutions 
were then gently aspirated from each well, and the formazan crystals within the cells were dissolved in 
DMSO ȝ/. Optical densities were read at 550 nm using a Multiskan Spectrum Thermo Electron 
Corporation reader. The results were expressed as % relative to vehicle-treated control (0.5% DMSO 
was added to untreated cells), and the IC50 values were determined by linear and polynomial regression 
analysis. Experiments were performed in triplicate. 
Growth inhibition of HCT116, HCT15, Messa and Messa/Dx5 tumor cell lines was evaluated 
using the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI). The cells in 
exponential growth were incubated for 72 h at different concentrations of the inhibitors. Then an 
equivalent of the CellTiter-Glo reagent was added, and the solution was mixed for 2 min in order to 
induce cell lysis. Luminescence was recorded after an additional time of 10 min. IC50 values were 
calculated using nonlinear regression analysis (GraphPad Prism statistics software). 
Cell viability of PC-3, RD and HepG2 cells was determined using the MTT colorimetric assay. 
PC-3 and RD cells were seeded into 24-well plates to a density of 95x103ȝ/ZHOO+HS*FHOOV
were seeded into 24-well plates to a density of 120x103ȝ/ZHOO$IWHUKRIJURZWK WRDOORZ
attachment of cells to the wells, test compounds were added at 0.01-ȝ0$IWHUKRIJURZWKDQG
UHPRYDORIWKHFXOWXUHPHGLXPȝ/ZHOORI3%6FRQWDLQLQJ ȝ0077ZDVDGGHG&HOOFXOWXUHV
were further incubated at 37 °C for 2 h in the dark. The solutions were then gently aspirated from each 
well, and the formazan crystals within the cells were dissolved in propan-2-olo and 0.04 N HCl (200 
ȝ/2SWLFDOGHQVLWLHVZHUHUHGDWQPXVLQJD0XOWLVNDQSpectrum Thermo Electron Corporation 
reader. The results were expressed as % relative to vehicle-treated control (0.1% DMSO), and IC50 
values were calculated by nonlinear regression analysis (GraphPad Prism statistics software). 
Experiments were performed in triplicate. 
Immunofluorescence and Light Microscopy. Cells were seeded in culture dishes containing 
sterile coverslips coated with poly-L-lysine. At the end of the indicated treatments, the cells were fixed 
in 3.7% paraformaldehyde, permeabilized in 0.1% Triton X-100 in PBS saline and processed for IF 
using primary antibodies to lamin B1 (ab16048, Abcam, Cambridge, UK),  active caspase-3 (ab13847, 
Abcam), or alpha-tubulin (clone B5.1.2, Sigma-Aldrich). Secondary antibodies were either conjugated 
to FITC (Jackson Immunoresearch Laboratories) or to rhodamine (Santa Cruz Biotechnology). The 
'1$ZDVVWDLQHGZLWKƍ,6-diamidino-2-phenylindole (DAPI). Samples were analyzed under a Nikon 
Eclipse 90i microscope equipped with a Qicam Fast 1394 CCD camera, and images were acquired 
using NIS-Elements AR 3.2 (Nikon). Unfixed cell cultures were observed under an inverted Nikon 
TE300 microscope with a 10x objective, and images were acquired using the ACT-1 software and a 
DMX1200 CCD (resolution 1280x1024 pixels). 
Flow Cytometric Analysis. Cell cycle distribution was analyzed after incubation with PI 
(Sigma-Aldrich), whereas apoptosis was analyzed with annexin V-FITC (Immunological Sciences, IK-
11120 or Becton Dickinson and Co., Milan, Italy) staining alone or with annexin V-FITC in 
combination with PI. Cell samples were analyzed in a Coulter Epics XL cytofluormeter (Beckman 
Coulter) equipped with EXPO 32 ADC software. At least 105 cells per sample were acquired and 
analyzed using BD CellQuest Pro Software. 
Gli-dependent Luciferase Reporter Assay. The luciferase assay was performed in Shh-Light 
II (Shh-L II) cells, stably incorporating a Gli-responsive luciferase reporter and the pRL-TK Renilla 
(normalization control), for 48 h with SAG (200 nM) and the studied compounds. Luciferase and 
renilla activity were assayed with a dual-OXFLIHUDVH DVVD\ V\VWHP DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V
instruction (Promega, Madison, WI, USA). Results are expressed as luciferase/renilla ratios and 
represent the mean ± SD of three experiments, each performed in triplicate. ARAP 18 and 23 did not 
modify the renilla activity. 
Pharmacokinetic studies. CD-1 mice (27 + 27), male, were used for the pharmacokinetic 
studies. The IV bolus was injected through the caudal vein at a dose of 5 mg/kg; the PO gavage was at 
a dose of 15 mg/kg. In a Sirocco Filter Plate (Waters), 100 µL of plasma were added to 300 µL MeOH 
spiked with 10 µL of IS (DDP-10228 1 µg/mL). The plate was shaken for 15 min and filtered under 
vacuum (15 mm Hg) for 5 min. The samples were analyzed by LC/MS/MS: Premiere XE; eluent: water 
(solution A), acetonitrile with 0.1% HCOOH (solution B), gradient from 2% B to 80% B up to 0.8 min, 
then 100% B up to 1.3 min, then 0.5 min 100% B; flow rate 0.5 mL/min; Column Acquity BEH C18, 
2.1x50 mm, 1.7 µm injection; YROXPHȝL; temp. column 50 °C. ESI positive, extractor 4V; capillary 
3.20kV; temp. source 115 °C; temp. desolv. 450 °C. The experiments were carried out in agreement 
with Italian Law (D.L. 116/92). 
Caco-2 Cell Permeability. Caco-2 cells (ECACC) were cultured in DMEM, 10% FBS, 1% 
NEAA, 10 mM Hepes buffer, 50 U penicillin, and 50 Pg/mL streptomycin and split at confluence by 
trypsinization. The cells (200000 cells/well) were seeded on Millicell 24-well cell culture plates. After 
24 h at 37 °C in a humidified and 5% CO2 containing atmosphere, the medium was exchanged for 
enterocyte differentiation medium with additives (Becton Dickinson), which allows Caco-2 cells to 
establish within 3 days a differentiated enterocyte monolayer. TEER, measured with a Millicell-ERS 
0LOOLSRUH&RUSPXVWEH!ȍ Transport across the Caco-2 monolayer was determined by adding 
a  ȝ0 VROXWLRQ RI test compound in DMEM (1% final concentration of DMSO) to the side from 
which permeability was to be determined. The $ĺ% WUDQVSRUW DFURVV&DFR-2 monolayer cells was 
determined by adding the test compound to the apical side at pH 6.5. After 2 h, the basolateral side 
solution at pH 7.4 and the apical and starting solutions ZHUHDQDO\]HGE\/&í0606,QWKH%ĺ$
experiment, the test compound was added to the basolateral side and collected on the apical side. 
Monolayer integrity was assessed with a lucifer yellow assay at the end of each experiment. The 
apparent permeability (Papp) was calculated as J/C0 ratio, where J is the flux (dX/dt per A) and C0 is 
the donor concentration ȝ0DWt = 0; dX/dt is the change in mass (X, nmol) per time (t, s), and A is the 
filter surface area (cm2). 
CYP450 Inhibition. Cytochrome P450 inhibition experiments were carried out according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQV%' Biosciences, Franklin Lakes, NJ, U.S.). Compound 22 was dissolved 
in a 96-ZHOOSODWHDWDȝ0 final concentration in potassium phosphate buffer (pH 7.4) containing an 
NADPH regenerating system. For all enzyme/substrate pairs, the final cofactor concentrations were 1.3 
mM NADP+, 3.3 mM glucose 6-phosphate, and 0.4 U/mL glucose 6-phosphate dehydrogenase. The 
reaction was initiated by the addition of specific isoenzymes (Supersomes, Gentest) and substrates at 
37 °C. Furafylline (for CYP1A2, 100 mM), sulfaphenazole (for CYP2C9, 10mM), tranylcypromine 
IRU&<3&ȝ0TXLQLGLQHIRU&<3' mM), and ketoconazole (for CYP3A4, 1.66 mM) 
were employed as control inhibitors in one-third serial dilution. Incubations were carried out for 15 min 
(0.5 pmol of CYP1A2, 5 mM 3-cyano-7-ethoxycoumarin), 30 min (0.5 pmol of CYP2C19, 25 mM 3-
cyano-7-ethoxycoumarin, 1 pmol of CYP3A4, 50 mM 7-benzyloxy-4-(trifluoromethyl)coumarin; 1.5 
pmol of CYP2D6, 1.5 mM 3-[2-(N,N-diethyl-N-methylamino)-ethyl]-7-methoxy-4-methylcoumarin), 
or 45 min (1 pmol of CYP2C9, 75 mM 7-methoxy-4-(trifluoromethyl)coumarin). The reaction was 
then quenched by adding 75 mL of a mixture containing 80% MeCN and 20% Tris base (0.5 m), and 
plates were read on a fluorimeter at the appropriate emission/excitation wavelengths. The percentage 
inhibition was calculated relative to enzyme samples without inhibitors. 
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vinorelbine; PTX, paclitaxel, ARAP, 3-aroyl-1-arylpyrrole; TMP, trimethoxyphenyl; MW, microwave; 
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